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Alzheimer’s disease is a complex disorder in 
which both genetic and environmental factors 
affect the risk and the onset age of the disease. 
This thesis investigates the effects of LDLR, 
SOAT1 and DHCR24 genes on the risk and the 
CSF biomarker levels in Alzheimer’s disease. 
The findings provide new information related 
to the possible gender-specific association of 
certain genetic variants with AD, which may 
be applied in the development of novel bio-
markers and treatment strategies for AD.
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ABSTRACT 
 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder leading to 
dementia. It affects about 7% of individuals living in the developed countries, who are 
older than 65 years, and the number of patients is expected to nearly double in the next 20 
years. According to the prevailing amyloid hypothesis, accumulation of β-amyloid (A  
peptide, released from amyloid precursorprotein (APP), in senile plaques outside of 
neurons, neurofibrillary tangles (NFT) composed of phosphorylated tau (ptau) inside 
neurons and the atrophy of specific brain regions, are the causal and pathological hallmarks 
of AD. In AD, synaptic dysfunction and a gradual loss of neurons due to toxic effects of A  
and ptau are suggested to lead to damages to the neuronal network that underlie proper 
brain function.  
Late onset AD (LOAD) is a complex disease where both genetic and environmental factors 
may affect the risk and onset of the disease. To date, genome-wide association studies 
(GWAS) as well as linkage analysis have not yet managed to unveil all LOAD associated 
genetic factors. In the past few years, over 20 novel risk loci have been discovered in GWAS 
studies. The identified loci can be aggregated into functional clusters of immune response, 
lipid metabolism and endocytosis pathways with majority of identified loci found nearby 
genes that can have an affect on either A  production, clearance or both. In addition, whilst 
certain genes affecting both the lipid metabolism and A  production have been found to 
have significant associations with LOAD risk or pathology in smaller case-control 
association studies. Although these genes have not been confirmed in large GWAS studies, 
they have been considered to be promising candidate genes in the pathogenesis of LOAD. 
The aim of this thesis was to elucidate some of these potential LOAD risk genes in a case-
control association study setting and to evaluate established LOAD-associated CSF 
biomarker levels between carriers of different alleles, genotypes and haplotypes. 
In study I, we genotyped six low density lipoprotein receptor (LDLR) single nucleotide 
polymorphisms (SNPs) and evaluated apolipoprotein E (APOE) 4 allele carrier status 
among Finnish AD patients and healthy controls. A certain SNP allele in the LDLR gene 
was found to be overrepresented in female AD patients and certain estimated haplotypes 
were found to be either under- or overrepresented in female AD patients. We measured 
A tau and ptau levels from a subgroup of AD patients and controls and consequently 
found that A levels were lower in the AD patients than controls and that the mean tau 
levels were higher in AD patients than controls.  We also found that in female AD patients, 
the CSF biomarker levels differed significantly in relation to different LDLR genotype and 
haplotype carriers. This suggests that the LDLR may associate with AD risk and the levels 
of CSF A tau and ptau in females and thus there might be one or more risk allele(s), 
which affect AD risk and can vary between subjects. It also appears that the association of 
certain LDLR gene polymorphisms and AD is a gender specific. 
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In study II we compared allele and genotypic distribution of four Sterol O-acyltransferase 1 
(SOAT1) SNPs and estimated the haplotype frequencies between AD patients and controls. 
We also measured levels of CSF biomarkers in genotype and haplotype carriers in a 
subgroup of AD patients and controls. The CC genotype of SNP rs2247071 was found to be 
overrepresented in AD patients. However, we did not find any significant differences 
between CSF levels of A tau and ptau in relation to different alleles, genotypes or 
haplotypes among AD patients. Our findings suggest that SOAT1 gene is only a minor risk 
factor in AD. 
 
In study III we genotyped four 24-dehydrocholesterol reductase (DHCR24) SNPs and 
compared allelic and genotypic distribution between AD patients and controls. We also 
measured the level of CSF biomarkers in genotype and haplotype carriers in a subgroup of 
AD patients and controls. We found that males carrying the T allele of SNP rs600491 had a 
significantly increased risk of AD and that the TT genotype was overrepresented in AD 
males as compared to control males. We also discovered that AD patients carrying the GG 
genotype of SNP rs718265 had significantly lower levels of A than AA and AG genotype 
carriers. This suggests that DHCR24 may be associated with AD risk and that this may be 
gender dependent via yet unknown molecular mechanisms.  
 
In summary, the work presented in this thesis provides new information on the genes 
involved in AD pathology and also reveals a possible gender specific effect of lipid 
metabolism gene variants on AD risk. These findings may further help to identify potential 
molecular mechanisms involved in AD pathogenesis and the development of novel 
anteceding and prognostic biomarkers for AD. 
 
National Library of Medicine Classification: WT 155, QU 470, QU 95 
Medical Subject Headings: Alzheimer Disease; Genes; Genetics; Genotype; Polymorphism, Genetic; 
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TIIVISTELMÄ 
 
Alzheimerin tauti (AT) on yleisin dementiaa aiheuttava neurodegeneratiivinen sairaus. Se 
koskettaa noin 7%:a länsimaiden yli 65-vuotiaista asukkaista ja sairastuvien määrän 
arvioidaan lähes kaksinkertaistuvan seuraavan 20 vuoden aikana. AT:n patologiaan 
kuuluvat amyloidiprekursoriproteiinista (APP) vapautuvan A -peptidin kasaantuminen 
solunulkoiseen tilaan, fosforyloituneen tau-proteiinin (ptau) kerääntyminen hermosolujen 
sisään ja tiettyjen aivoalueiden surkastuminen. AT:ssa A :n ja ptau-kimppujen myrkyllinen 
vaikutus johtaa synapsien toimintahäiriöön ja etenevään hermosolukatoon mikä puolestaan 
johtaa häiriöihin hermoverkon toiminnassa ja AT:n kliiniseen puhkeamiseen. 
 
On arvioitu että myöhäisiän AT:n (LOAD:n) kehittymiseen ja riskiin vaikuttavat 
monimutkaisella tavalla sekä geneettiset että ympäristötekijät. Toistaiseksi uusimmat 
genomin laajuiset assosiaatiotutkimukset (GWAS) ovat onnistuneet löytämään vasta osan 
geneettisistä tekijöistä jotka lisäävät LOAD:n riskiä. Viime vuosina yli 20 uutta riskialuetta 
on löydetty GWAS-tutkimuksissa. Alueilla sijaitsevat geenit ryhmittäytyvät pääosin 
immuunipuolustukseen, rasva-aineenvaihduntaan, sekä endosytoosi-reaktiopolkuihin 
vaikuttaviin tekijöihin niin, että suurin osa näistä geeneistä vaikuttaa A -peptidin 
tuotantoon ja hajotukseen jollakin tavalla. Eräät aivojen rasva-aineenvaihduntaan ja A -
peptidin tuotantoon vaikuttavat geenit, jotka eivät ole nousseet merkittäviksi laajoissa 
GWAS-tutkimuksissa isoilla väestöillä tutkittuna, ovat liittyneet LOAD:n riskiin tai 
patologiaan pienemmissä tapaus-kontrollitutkimuksissa. Niitä pidetään tämän takia 
lupaavina kandidaattigeeneinä AT:n kehittymiselle. Tämän väitöksen tarkoitus oli tutkia 
eräitä näitä mahdollisia LOAD:n riskigeenikandidaatteja tapaus-kontrolli – 
tutkimusasetelmassa ja myös arvioida LOAD-potilaiden aivo-selkäydinnesteen 
merkkiaineiden tasoja geenien eri alleelien, genotyyppien ja haplotyyppien kantajien 
kesken. 
 
Tutkimuksessa I selvitimme kuuden matalatiheyksisen lipoproteiinin (LDL:n) reseptorin 
geenin (LDLR) yhden nukleotidin polymorfioiden (SNP:ien) alleelien ja apolipoproteiini E 
(APOE) 4 – alleelin esiintymistä suomalaisilla LOAD-potilailla ja terveillä 
kontrollihenkilöillä. Erään LDLR-geenin SNP-alleelin havaittiin olevan yleisemmän 
naispuolisilla LOAD-potilailla. Alleelien kytkeytymisen perusteella muodostetut 
haplotyypit olivat joko ali- tai yliedustettuina naispuolisilla LOAD-potilailla. Mittasimme 
selkäydinnesteen A tau- ja ptau-tasot osalta LOAD-potilaista ja kontrolleista ja 
havaitsimme että A -tasot olivat matalampia LOAD-potilailla kuin kontrollihenkilöillä ja 
keskimääräiset tau-proteiinin arvot olivat korkeampia LOAD-potilailla kuin 
kontrollihenkilöillä. Havaitsimme myös että LOAD-naisilla aivo-selkäydinnesteen 
merkkiainepitoisuudet vaihtelivat merkittävästi eri LDLR genotyyppien ja haplotyyppien 
kantajien kesken. Näin ollen on mahdollista että LDLR on eräs LOAD:n riskigeeneistä ja 
selittää aivo-selkäydinnesteen merkkiaineiden pitoisuuseroja. Vaikuttaa myös siltä että 
VIII 
 
 
tiettyjen LDLR geenin polymorfioiden ja LOAD:n riskin välinen yhteys on sukupuolesta 
riippuvainen. 
 
Tutkimuksessa II vertasimme neljän steroli o-asyylitransferaasi 1 (SOAT1)-geenin SNP:ien 
alleelien ja genotyyppien sekä niistä muodostettujen haplotyyppien esiintyvyyttä potilailla 
ja kontrolleilla. Mittasimme myös aivo-selkäydinnesteen merkkiainepitoisuudet eri 
genotyyppien ja haplotyyppien kantajien kesken pienemmässä otosryhmässä. Genotyyppi 
CC SNP:stä rs2247071 osoittautui olevan yliedustettuna LOAD-potilailla verrattuna 
kontrollihenkilöihin. Emme löytäneet mitään merkittävää eroa A tau- ja ptau-tasoissa 
eri alleelien, genotyyppien tai haplotyyppien kantajien kesken. Löytömme viittaavat siihen, 
että SOAT1-geenin muutoksilla ei ole merkittävää roolia LOAD:n riskin muodostumisessa. 
 
Tutkimuksessa III vertasimme seladin-1-proteiinia koodaavan geenin DHCR24 neljän 
SNP:n alleelien ja genotyyppien esiintyvyyttä LOAD-potilailla ja kontrollihenkilöillä. 
Mittasimme myös aivo-selkäydinnesteen merkkiaineiden pitoisuuden eri genotyyppien ja 
haplotyyppien kantajilla osassa tutkimusryhmää. Havaitsimme, että miehillä, jotka 
kantoivat rs600491:n T alleelia, oli merkittävästi suurentunut LOAD:n riski ja että 
genotyyppi TT oli yliedustettuna LOAD-miehillä verrattuna kontrollimiehiin. Havaitsimme 
myös, että LOAD-potilailla joilla oli SNP:n rs718265 GG genotyyppi oli huomattavasti 
matalammat A -proteiinin tasot kuin AA- tai AG-genotyypin kantajilla. Tämä viittaa 
siihen, että DHCR24 voi olla kytkeytynyt LOAD:n riskiin ja että riski voi olla sukupuolesta 
riippuvainen jollakin toistaiseksi tuntemattomalla mekanismilla. 
 
Yhteenvetona voi todeta, että tämä väitös antaa uutta tietoa geeneistä jotka ovat osallisina 
LOAD:n patologiaan ja riskiin ja tuo esille mahdollisen rasvahappoaineenvaihduntaan 
osallistuvien geenien sukupuolesta riippuvaisen vaikutuksen LOAD:n riskiin. Nämä 
havainnot voivat auttaa tunnistamaan potentiaalisia molekulaarisia mekanismeja jotka 
vaikuttavat LOAD:n patologian kehittymiseen sekä edesauttavat uusien LOAD:a 
paremmin ennakoivien biologisten merkkiainesovellusten kehittämistä. 
 
 
Luokitus: WT 155, QU 470, QU 95 
Yleinen Suomalainen asiasanasto: Alzheimerin tauti; geenit; perinnöllisyystiede; genotyyppi; riskitekijät; 
reseptorit; aivo-selkäydinneste; merkkiaineet 
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 1 Introduction 
Dementia has several different etiologies of which Alzheimer’s disease (AD) is the most 
common neurodegenerative disorder followed by vascular cognitive impairment (VCI) and 
dementia with Lewy bodies (DLB) (LoGiudice & Watson 2014).  In AD, A  peptides 
accumulate, and in time, produce senile plaques outside of neurons. In addition,  
neurofibrillary tangles (NFTs) consisting of phosphorylated tau (ptau) accumulate inside 
neurons resulting in a toxic effect in these cells that leads to their death and the subsequent 
atrophy of affected brain areas (Montine et al. 2012). These harmful effects lead to 
progressive cognitive decline, associated behavioral symptoms and finally to death. 
Currently there are no effective preventive therapies or cure for AD available and the 
symptoms can only be treated in a palliative sense (Brookmeyer et al. 2007). 
 
The apolipoprotein E (APOE) gene 4 allele is known to markedly increase the risk of 
developing both sporadic and familial AD (Saunders et al. 1993) but other genetic and 
environmental factors that increase the risk of sporadic form of the disease have yet to be 
fully discovered. Most AD patients suffer from the late onset type AD (LOAD) but some 
suffer from early onset familial AD (EOAD), which is known to be heritable. EOAD is 
known to be associated with mutations in the amyloid beta (A ) precursor protein (APP) 
gene (Hardy 1997), presenilin 1 (PSEN1) gene (Sherrington et al. 1995) and presenilin 2 
(PSEN2) gene (Levy-Lahad et al. 1995). Only around 50% of the LOAD patients carry an 
APOE 4 allele (Saunders et al. 1993) so there are also other genetic factors that modify 
LOAD risk. It has been estimated that LOAD incidence and progression of the disease 
involves multiple genetic and environmental factors (Bergem et al. 1997, Meyer & Breitner 
1998). So far recent genome-wide association studies (GWAS) have not managed to unveil 
all of the genetic factors affecting LOAD risk (Maher 2008). 
 
There are many studies that have investigated possible genetic associations with LOAD 
(later in this thesis referred as AD if not otherwise noted) risk. Dozens of genes have been 
suggested to be AD related but only few in addition to APOE have survived to be 
replicated in meta-analysis between independent populations and remain statistically 
significant (Bertram et al. 2007).  To overcome this problem a new approach, GWAS 
(Hirschhorn 2009), with larger test population sizes, has been introduced to AD research. 
Risk loci found in GWAS studies (excluding APOE) have been shown to alter AD risk by 
displaying odds ratios (OR) of approximately 1.1-1.15 at best (Karch et al. 2014). There are 
sometimes several genes in one locus which makes the functional alleles associated with 
AD risk hard to discover (Karch et al. 2014). In the past years, over 20 novel risk loci have 
been discovered in the GWAS studies, with most in non-Hispanic white or European 
ancestry (Reitz & Mayeux 2014). The identified loci mainly cluster,in functional terms, 
around immune response, lipid metabolism and endocytosis pathways (Reitz & Mayeux 
2014) with majority of genes affecting the A  production and clearance (Karch et al. 2014). 
As EOAD patients carry mutations that lead to the accumulation of A  peptide in senile 
plaques (Levy-Lahad et al. 1995, Sherrington et al. 1995, Hardy 1997) and senile plaques 
exist also in AD, it has been hypothesized that β-amyloid metabolism is a key process in 
AD progression and pathology (Hardy & Selkoe 2002). The amyloid hypothesis proposes 
that the aggregation of Aβ initiates the pathologic and clinical changes associated with AD 
and that the tau protein aggregation results from these changes (Karch et al. 2014). 
 
GWAS studies involve a high significance threshold which may lead to a loss of sensitivity 
(McCarthy et al. 2008). Certain genes affecting both the lipid metabolism and A  
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production have not been found to be associated significantly with AD risk in large GWAS 
studies, but instead have been found to have significant associations with AD risk or AD 
pathology in smaller case-control association studies (Greeve et al. 2000, Hutter-Paier et al. 
2004, Cheng et al. 2005, Gopalraj et al. 2005, Iivonen 2005). Due to the significant findings in 
the association studies those genes have been considered to be promising candidates for 
further association studies despite of the GWAS results. The low density lipoprotein 
receptor (LDLR) encoded by gene LDLR has been shown to enhance A clearance by 
directly binding it and trafficking it to astrocytes for degradation (Basak et al. 2012a). 
Seladin-1, encoded by gene DHCR24, is a cholesterol synthesizing enzyme that has been 
shown to take part in formation of cholesterol rich detergent resistant lipid rafts (DRMs) 
(Crameri et al. 2006) and also protect cells against A  mediated toxicity (Greeve et al. 
2000). Sterol O-acyltransferase 1 (SOAT1) encoded by gene SOAT1, metabolizes cholesterol 
into cholesterol esters (Zhang et al. 2003) and therefore modulates A  production via 
modulating the cholesterol/cholesterol ester ratio (Puglielli et al. 2001).   
 
AD is a disease which is probably governed by risk and protective genetic variants in 
several different genes and its progression might be influenced by numerous 
environmental and post-translational factors (Karch & Goate 2015). The amyloid hypothesis 
is one possible explanation for AD pathology and more studies are needed to further 
evaluate AD risk factors and their impact on β-amyloid metabolism.  
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2 Review of the literature 
2.1 CLINICAL AND NEUROPATHOLOGICAL CHARACTERISTICS IN 
ALZHEIMER’S DISEASE 
 
2.1.1 Clinical features and diagnosis of Alzheimer’s disease 
 
Clinical features of AD include impairment of declarative memory, which often is one of 
the early signs of AD (Tarawneh & Holtzman 2012) following a long preclinical phase of 
the disease. It has been proposed, that the measurement of the memory impairment, using 
a complex measuring technique named as lexical semantic conceptual deficit (LSCD), 
would even be used as a screening method in early stage AD (Guerrero et al. 2015). 
Patient’s ability to perform normal daily life actions starts to, consistently and 
progressively, decline (Morris 1993) with simultaneous amnestic memory impairment 
which distinguishes it from normal aging (Rubin et al. 1998). Personality and behavioral 
changes including depression and withdrawal (Zubenko et al. 2003) are also common in 
early AD. With disease progression, more severe symptoms like psychosis, paranoia and 
agitation (Reisberg et al. 1996) occur among many patients, in addition to the worsening 
memory impairment. Finally, in the severe stages of AD patients lose their ability to talk, 
maintain themselves or eat without assistance and need constant care. This poor physical 
condition leads then gradually to malnutrition, sensitivity to infections and finally death.  
 
Mild cognitive impairment (MCI) is a condition in which there is a measurable decline in 
person’s cognitive ability but the person is still able to manage normal everyday activities 
(Forrester et al. 2015). MCI is an independent risk factor of AD (Manly et al. 2008, Forrester 
et al. 2015) but there is also a possibility that some of the MCI patients are in fact suffering 
from early AD (Sperling et al. 2011). 
 
Dementia is often defined based on the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) criteria released by the American Psychiatric Association (American 
Psychiatric Association 2013). The latest DSM (DSM-5) incorporates dementia both into the 
categories of major and mild neurocognitive disorders. Another often used benchmark in 
AD diagnosis are the National Institute on Neurological and Communicative Disorders and 
Stroke and the Alzheimer Disease and Related Disorders Association (NINCDS/ADRDA) 
criteria (McKhann et al. 1984). As AD is characterized by loss of memory and other 
cognitive impairments with shortened life expectancy and increased mortality (Rait et al. 
2010), it is often more useful to diagnose AD according to NINCDS/ADRDA criteria to 
“probable”, “possible” or “definite” AD instead of  evaluating patient’s level of  dementia 
into DSM “major” or “mild” dementia cathegory.   
Evaluation of cognitive and behavioral performance in suspected dementia can be done 
using clinical measures such as the Mini-Mental State examination (Folstein et al. 1975) and 
tests for episodic memory such as the Short Blessed Test (Carpenter et al. 2011). The 
performance testing can be done periodically to evaluate the disease progression and state 
of dementia.  
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To rule out any treatable or concomitant disorders such as hydrocephalus, chronic subdural 
hematoma or cerebrovascular disease that could cause cognitive decline, and to support the 
possible AD diagnosis, structural neuroimaging with computed tomography or magnetic 
resonance imaging should be included in the diagnostic regime (Mosconi et al. 2010). In 
AD, progressive size reduction and atrophy (Shen et al. 2011, Shaerzadeh et al. 2014) can be 
seen in the hippocampus, frontal cortex and limbic areas involved in complex learning and 
memory functions (Figure 1).  
 
 
 
 
 
Figure 1. Hippocampal atrophy. Left: the hippocampus outlined in red shows no atrophy. Right: 
atrophy is severe. (Reproduced from Shen et al., 2011, Alzheimer's & dementia: the journal of 
the Alzheimer's Association 2011;7:e101-8, with the kind permission of Elsevier).  
 
2.1.2 Neuropathology in AD 
 
Neuropathological hallmarks of AD include the accumulation of Aβ peptides outside of 
neurons (Masters & Selkoe 2012), the gradual formation of senile plaques and intraneuronal 
accumulation of NFTs (Montine et al. 2012). In the healthy individual, the majority of APP 
is further processed by - and -secretases leading to nonpathogenic sAPP  peptide and -
C-terminal fragment (CTF) (Thinakaran & Koo 2008). Some APP is, on the other hand, 
cleaved by - and -secretases at the N- and C-termini leading to pathogenic A  peptides 
(Karch et al. 2014, Salminen et al. 2013) (Figure 2). In AD, the pathogenic route starts to 
dominate leading to the accumulation of more A  peptides (Masters & Selkoe 2012). These 
processes cause neuronal degeneration, atrophy and inflammation in the affected brain 
areas (Shen et al. 2011, Shaerzadeh et al. 2014).  
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Figure 2. β-amyloid (Aβ) production and degradation. APP is processed into sAPPα or sAPPβ 
peptides and C83 or C99 fragments that are further processed into either non-pathogenic p3 
fragments or pathogenic Aβ40/42 peptides. (Image modified from Salminen et al., 2013, Progress 
in neurobiology 2013;106-107:33-54).  
 
 
A histological examination is often needed to distinguish AD from other disorders 
(Montine et al. 2012) (Figure 3). Senile plaques are largely composed of A  fibrils consisting 
of non-soluble -sheet structure deposited in the extracellular space between neurons 
(Masters & Selkoe 2012). Senile plaques start to accumulate early in the course of AD 
development in the neocortex and then through allocortex, diencephalon, striatum, basal 
forebrain cholinergic nuclei, brainstem nuclei and cerebellum in later disease stages (Thal et 
al. 2002). 
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Figure 3. Photomicrograph of the temporal cortex of a patient with Alzheimer's disease 
(modified Bielschowski stain; original magnification, 40x). Numerous senile plaques (black 
arrow) and NFTs (red arrow) are shown. (Reproduced from Perl, 2010, The Mount Sinai journal 
of medicine, New York 2010;77:32-42, with the kind permission of John Wiley and Sons).   
 
 
 
NFTs are formed from aggregated and abnormally hyperphosphorylated axonal tau (ptau) 
protein particles which lose their normal function as microtubule stabilizing proteins and 
accumulate in the somatodendritic compartment of cells (Kidd 2006, Spillantini & Goedert 
2013) as straight and paired helical filaments. NFTs (Figure 3) start to develop in the 
entorhinal cortex and before appearing progressively through the hippocampus, 
association cortices and primary sensory areas in a stereotypic fashion related to disease 
severity (Braak & Braak 1991). Abnormality in the adjacent neurons and processes can be 
seen due to the toxic effect (DeKosky & Scheff 1990, Masliah et al. 1993) of both Aβ and 
NFTs (Figure 4).  
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Figure 4. Structural Changes in the AD Brain. The neural circuitry involved in memory including 
the entorhinal cortex-hippocampal circuitry (A) (dentate gyrus as DG, Hippocampal Cornu 
Ammonis areas as CA1 and CA3)  are severely affected by AD pathology, including the 
deposition of plaques (blue) and tangles (green) accompanied with dramatic neuronal and 
synapse loss. In addition, there are structural changes to remaining neurons aswell, in the AD 
brain, that are thought to contribute to neural circuit disruption and cognitive impairments (B), 
including damage to neurites in the halo of soluble amyloid beta surrounding plaques, tau 
aggregation in cell bodies and neurites, and the loss of synapses associated with oligomeric Aβ 
around plaques. (Reproduced from Spires-Jones & Hyman, 2014, Neuron 2014;82:756-771, 
with the kind permission of Elsevier).  
 
 
 
Neurofibrillary tangle extent and distribution have been shown to correlate with the degree 
of dementia (Bierer et al. 1995) and also with the duration of the illness in general 
(Arriagada et al. 1992). In addition, a substantial 45% loss of synapses (Terry et al. 1991) has 
been shown to occur in AD brains compared to control brains and to correlate strongly with 
a degree of functional impairment typical for AD. In addition, inflammation and oxidative 
damage (Querfurth & LaFerla 2010), loss of white matter, cerebral amyloid angiopathy 
(CAA) (Spires-Jones & Hyman 2014) and degeneration of basal forebrain, with concurrent 
reduction of acetylcholine metabolism (Burns et al. 1997), are also symptoms of AD 
progression. 
 
2.1.3 Non-genetic risk and protective factors of AD 
 
AD is believed to be caused by multiple genetic and environmental factors affecting each 
patient individually. There are some common non-genetic variables that have been found 
to be AD risk modulators. Age is considered to be the greatest risk factor for AD as the risk 
of AD doubles every five years after the age of 65 (www.alz.org). Some disorders like type 
2 diabetes (Leibson et al. 1997, Luchsinger 2010), which nearly doubles the AD risk, 
metabolic syndrome (Raffaitin et al. 2009, Yaffe et al. 2009) as well as previous brain injury 
(Guo et al. 2000) and depression, (Butters et al. 2008) are all established risk factors of AD.  
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Some lifelong environmental and lifestyle factors have been found to modulate AD risk. 
Intellectual efforts like education and other cognitively stimulating activity seem to reduce 
the overall risk of AD (Fratiglioni & Wang 2007, Carlson et al. 2008, Imtiaz et al. 2014). 
Lifestyle choices like consumption of a Mediterranean diet rich with plant foods and fish as 
well as avoidance of red meat are associated with a reduced risk of developing AD (Gu et 
al. 2010, Di Marco et al. 2014) possible due to the favorable effects of polyunsaturated fats 
on inflammatory processes and neuronal functions (Calder 2009). On the contrary, heavy 
smoking in midlife has been found to increase the AD risk (Rusanen et al. 2011) possibly 
due to the vascular damage that it causes. Hypertension has also been considered to 
increase the risk of AD (Qiu et al. 2005). Regular exercise, on the other hand, has been 
suggested to mitigate AD symptoms and slow AD pathology formation (Larson et al. 2006, 
Farina et al. 2015). 
 
 
2.1.3.1 Cholesterol and AD risk 
The pathophysiology of AD has many connections with lipid metabolism. The APOE 
lipoprotein is the main cholesterol transport protein in the brain (Poirier et al. 2014) and its 
gene, especially allele ε4, is the most important AD risk gene found yet (Corder et al. 
1993a). APOE transports cholesterol that is needed for membrane remodeling (Poirier 2003) 
from astrocytes to neurons for dendritic and synaptic formation. An APOE-cholesterol 
assembly organized in the microglia or astrocytes leaves the cell, attaches to LDL receptor 
and is internalized into the remodeling nerve cell (Figure 5). In addition, APOE is 
hypothesized to be involved in clearance and deposition on A  and that the lipidation 
status of APOE would affect this process (Jiang et al. 1994). LDL receptor has also been 
shown to directly bind A  and enhance its clearance by astrocytes (Basak et al. 2012).  
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Figure 5. A hypothesis for the mechanism of cholesterol–phospholipid recycling in the injured 
central nervous system. Degenerating synaptic terminals are internalized by astrocytes and 
microglia, and degraded to release non-esterified cholesterol (a), which can be used as free 
cholesterol (FC) for the assembly of apolipoprotein E (APOE)–cholesterol–lipoprotein complexes 
(b) or converted, by the acetyl coenzyme A:cholesterol acyltransferase (SOAT1) into cholesterol 
esters (CE) for storage purposes. Newly formed APOE–cholesterol–lipoprotein complexes are 
directed to the circulation (presumably through the ependymal cells that surround the 
ventricles) and/or to specific brain cells requiring lipids. In the latter case, APOE complexes are 
thought to be internalized (c) after binding to a neuronal member of the low-density lipoprotein 
(LDL) receptor family (e.g. the LDL receptor, the very-low-density-lipoprotein receptor, or the 
APOE–LDL-receptor-related protein). Cholesterol is then released in esterified form (d) and can 
be converted to FC (e) for use in dendritic proliferation and/or synaptogenesis (f). As a 
consequence of the internalization process, de novo cholesterol synthesis via the mevalonate 
pathway is repressed. Abbreviations: E, APOE; HDL, high-density lipoprotein; PL, phospholipid. 
(Reproduced from Poirier, 2003, Trends in Molecular Medicine 2003;9:94-101, with the kind 
permission of Elsevier). 
 
 
 
Midlife dyslipidaemia (an abnormal amount of cholesterol species in the plasma) is a 
known risk factor for cardiovascular disease (Prospective Studies Collaboration et al. 2007) 
but it is still debatable if it has any significant effect on AD risk. Some studies have found 
no association between elevated midlife total blood cholesterol and AD risk (Tan et al. 2003, 
Li et al. 2005) while some suggest the contrary position to be true (Solomon et al. 2009, 
Whitmer et al. 2005, Notkola et al. 1998). In a retrospective cohort study conducted in USA 
(Solomon et al. 2009), the blood cholesterol levels from 40-45 year old participants were 
measured and incidence rate of AD or vascular dementia was detected in a follow up time 
lasting 20-25 years. There was a trend (p = 0.06) for high midlife cholesterol to increase the 
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risk of AD and when a Cox proportional hazard model was used to distinguish the effect of 
different cholesterol levels on AD risk, the high total cholesterol was found to be 
significantly associated with AD risk (Solomon et al. 2009). In contrast, a longitudinal 
study, lasting for 40 years, with middle aged Swedish males, found no relation between 
total blood cholesterol levels and AD risk (Ronnemaa et al. 2011). 
In a study conducted by Kuo et al. 1998 AD patients had significantly higher LDL and 
lower HDL cholesterol levels in blood as well as higher A 40 and A 42 levels in the cerebral 
cortex compared to controls, as measured post mortem. There was also a correlation 
between blood total and LDL cholesterol levels and cerebral A 42 found in AD patients but 
not in controls (Kuo et al. 1998) which was independent of APOE genotype. Significant 
drops in cholesterolemia have been reported to occur days before death in previous studies 
(Smith et al. 1992, Zimetbaum et al. 1992). It is therefore possible, that the cholesterol levels 
of the patients from the Kuo et al. study may have also dropped before death and that the 
cholesterol levels would have been higher if measured earlier (Kuo et al. 1998). A post 
mortem study with individuals over 40 years of age, with absence of neurological disease, 
other than few cases of AD or stroke (Pappolla et al. 2003) found, that there was a 
relationship between cholesterolemia and early β-amyloid deposition in a dose dependent 
manner while the patients were still living. In a post mortem study with Japanese American 
men, low level of total blood cholesterol in midlife was associated with fewer neocortical 
neurofibrillary tangles 20 years later (Launer et al. 2001). In addition, a recent study 
measuring the A  levels in the brains of the healthy, non-demented elderly found an 
association between blood LDL cholesterol levels and cerebral amyloidosis (Reed et al. 
2014). Then a longitudinal study (Mielke et al. 2005) starting with 70 year old individuals 
lasting for 18 years found that increasing total cholesterol levels actually protects from 
dementia.  
The association findings between blood total cholesterol levels or LDL cholesterol levels 
and AD may considerably depend on when the levels that were measured (Panza et al. 
2006). It is known that blood cholesterol levels tend to drop late in life due to the normal 
aging process from the midlife levels (Ferrara et al. 1997) and several underlying diseases, 
including AD progression (Solomon et al. 2007), cause it to diminish, so it is sometimes 
difficult to estimate the original baseline level before the changes due to illness or aging has 
occurred. This may partly explain some of the controversial results concerning the 
associations found between blood cholesterol levels and AD 
risk/amyloidosis/neurofibrillary tangles in different age groups. It is also possible that the 
blood cholesterol levels reflect some other factors that affect AD risk and progression of AD 
pathology (Blennow et al. 2015a), are not themselves risk modulators of AD and are 
therefore casual associates and not causal, in relation to this disease. 
It has been proposed that cholesterol in plasma would not be able to enter the brain due to 
the blood brain barrier and thus plasma cholesterol levels would not affect brain cholesterol 
levels (Dietschy 2009, Kirsch et al. 2003) that are synthetized directly in the central nervous 
system (CNS). Endogenous cholesterol synthesis in CNS is regulated primarily by a 3-
hydroxy-3-methylglutaryl-coenzyme-A (HMGCoA) reductase which is needed to produce 
mevalonate, a key cholesterol precursor molecule (Poirier 2003). Excess CNS cholesterol is 
converted to 24S-hydroxycholesterol (24-OH), which is able to cross the blood brain barrier 
and thus leave the brain. 24-OH has been shown to act as a signalling molecule enhancing 
APOE gene transcription-  and its protein product synthesis and secretion (Leoni & Caccia 
2013) as well as stimulate the APP-targeting -secretase activity (Famer et al. 2007). 
Another metabolite produced from cholesterol, 27-hydroxycholesterol (27-OHC), is 
produced mainly in extra-hepatic organs outside CNS as a part of the bile acid synthesis 
pathway (Leoni & Caccia 2013). Atherosclerosis patients tend to have an elevated level of 
27-OHC in blood (Babiker et al. 2005, Karuna et al. 2011). In contrast to cholesterol, 27-OHC 
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has been shown to cross blood brain barrier (Heverin et al. 2005) as well as increase A  
production and oxidative stress in human cell lines (Dasari et al. 2010, Prasanthi et al. 2009). 
The level of 27-OHC has been found to be increased in the brain samples collected from AD 
patients (Heverin et al. 2004). It has also been proposed, that ApoAI, another 
apolipoprotein, which binds cholesterol in blood, is able to cross blood brain barrier and 
affect cholesterol metabolism in the brain that way (Stukas et al. 2014) and also reduce 
A induced toxicity by binding A directly (Lefterov et al. 2010, Paula-Lima et al. 2009). 
Finally, individuals with high blood ApoAI levels have been suggested to have a 
significantly lower risk of dementia (Saczynski et al. 2007).  
Lipids are major constituents in the plasma membrane with cholesterol being an important 
factor influencing its biological functions and stiffness (Burns & Rebeck 2010). In an 
experimental assay (Bodovitz & Klein 1996, Czech et al. 2007), methyl- -cyclodextrin 
treatment, used to decrease the amount of cholesterol in cell membranes, lead to a 
simultaneous reduction of APP cleaving activity of -secretase and an increase in -
secretase activity, which resulted in a reduction of A 40 and A 42 in the extracellular space. 
It has been speculated that -secretase would mainly cleave APP in cholesterol rich 
detergent resistant lipid rafts (DRMs) (Ehehalt et al. 2003) and that cholesterol would bring 
APP near -secretase in them (Simons et al. 1998). Thus reduction of cholesterol amount in 
plasma membrane would decrease APP load in DRMs (Simons et al. 1998, Marquer et al. 
2011) and lead to decreased A 42 production via decreased -secretase cleavage. It has also 
been claimed that cholesterol can directly bind to APP -secretase cleaving site and by 
blocking it, enable cleavage by -secretase to occur more readily (Yao & Papadopoulos 
2002). 
 
2.1.4 CSF biomarkers in AD 
 
Biomarkers are tools to monitor the progression of a disease and to set prognosis but at best 
they have a predictive value in diagnostics (Siemers 2009). Dubois and colleagues have 
presented criteria for diagnosing probable AD with tests that demands a presence of 
measurable memory deficit and at least one of the following findings: typical structural 
imaging changes seen in AD, AD specific CSF biomarker level changes, AD specific 
molecular and metabolic changes in a PET scan, or an identified dominant mutation 
leading to AD (EOAD) (Dubois et al. 2007). In AD, cerebrospinal fluid (CSF) levels of A 42, 
tau and ptau have been found to act as supporting tools in diagnosis and in the evaluation 
of AD progression (Vandermeeren et al. 1993, Blennow et al. 1995, Motter et al. 1995). 
Elevated ptau levels have been shown to be the most AD specific amongst CSF biomarkers 
(Meredith et al. 2013). Whilst the sensitivity of A 42, tau and ptau to predict AD (Schmand 
et al. 2010) in preclinical cases is limited (effect size 0.91-1.11), they can be used to evaluate 
the disease progression and β-amyloid load in the brain (Grimmer et al. 2009, Tapiola et al. 
2009, Samgard et al. 2010, Sweeney et al. 2015). 
CSF resides in the brain ventricles and subarachnoid space. Proteins in the CSF reflect the 
metabolic processes in the brain (Reitz & Mayeux 2014). The associations found between 
CSF biomarkers and senile plaque A  deposits or NFTs are not yet fully understood (Reitz 
& Mayeux 2014) but it has been suggested that levels of soluble A  in the CSF would 
decrease as insoluble amyloid plaque burden grows (Fagan et al. 2006, Degerman 
Gunnarsson et al. 2010, Grimmer et al. 2009). Inconsistent evidence stands for any 
correlation between CSF ptau levels and amount of NFTs (Buerger et al. 2006, Buerger et al. 
2007, Engelborghs et al. 2007) but tau and ptau levels have been found to markedly increase 
in AD patients compared to controls (Blennow et al. 2015b).  
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CSF biomarkers are often used in genetic AD association studies to evaluate possible 
connections between gene polymorphisms and AD pathogenesis. It has been implied that 
defining AD patients and controls according to the level of CSF biomarkers would increase 
the power of the genetic association study (Schott & ADNI Investigators 2012). Biomarker 
levels in patients and controls may more reliably reflect AD pathogenesis (Shaw et al. 2009) 
than classification normally used in association studies with clinically diagnosed and not 
pathologically confirmed patients and controls (Schott & ADNI Investigators 2012). 
2.2 GENETICS, EPIGENETICS AND TRANSCRIPTOMICS OF AD 
 
2.2.1 Identification of AD associated risk genes 
 
 
2.2.1.1 Candidate gene SNP analysis 
Large number of genetic factors, post-translational modifications and environmental factors 
interact and affect the phenotype outcome (Marian 2012). Inter-individual genetic 
differences in complex heritable disease phenotypes can be represented by single 
nucleotide polymorphisms (SNPs) that either contribute directly to susceptibility to 
common diseases, or more commonly, by being nearby elements that are actually the cause 
of the variation, by acting as surrogates for disease associated genetic hotspots as they are 
in linkage disequilibrium with them (Suh & Vijg 2005). It has been suggested that in every 
human genome there are 50-100 variants known to be associated with inheritable diseases 
in a complex manner and that the effects of polymorphisms range from indiscernible to 
significant (Marian 2012). Candidate gene studies have traditionally been focused on genes 
of proteins, lipids and carbohydrates that have been found related to the disease in 
previous studies and suggested to have a role in disease development (Patnala et al. 2013). 
Linkage disequilibrium (LD) studies with chromosomes found to be associated with a 
disease, and recently also GWAS studies, give good candidate genes for further SNP 
analysis (Marian 2012). There are several online applications which can help choosing the 
candidate gene. For instance, OMIM® database (www.ncbi.nlm.nih.gov/omim and 
www.omim.org) lists known genotype to phenotype correlations and is constantly 
maintained (Amberger et al. 2011).  
After selection of the candidate gene, the SNPs for the study have to be selected. Some 
SNPs may already have been associated with the disease risk in previous studies and it is 
usually feasible to include those SNPs in the study. The SNPs should be selected in a 
manner that would maximize the probability for a causative mutation to be in LD with 
them (De La Vega et al. 2006). The study SNPs should also have a high enough minor allele 
frequency to ensure power in calculations. Gene locus information (i.e. Entrez Gene: 
www.ncbi.nlm.nih.gov/Entrez or The UCSC Genome Browser: genome.ucsc.edu/) 
consisting of gene’s functional and structural elements, splice variants and regulatory 
elements, are needed for deciding which loci of the gene should be taken into study 
(Wheeler et al. 2005, Kuhn et al. 2009). There are also many different databases and 
softwares that provide data for selecting study SNPs (i.e. www.appliedbiosystems.com/, 
www.1000genomes.org/ and hapmap.ncbi.nlm.nih.gov/) (De La Vega et al. 2006, 
International HapMap Consortium 2003, 1000 Genomes Project Consortium et al. 2012).   
The SNPs in regulatory and intronic areas may have a role in regulating the transcriptional 
efficiency, gene expression or splicing of the gene (Wang et al. 2005, Maurano et al. 2012) 
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and are in that sense feasible for association analysis of risk genes with presumably low OR 
(Patnala et al. 2013). Single SNP analysis is performed by genotyping case and control 
samples according to the SNP and calculating the allelic and genomic frequencies between 
groups. The possible distribution differences between groups can be calculated with 
Pearson's χ2 test and Fisher's exact test. 
The SNPs that demonstrate LD with each other in a locus have been found to be conserved 
in populations and LD analysis can be used to find the limits of that conserved region 
(Ardlie et al. 2002). These SNPs in LD form a haplotype. The statistical power of an 
association test is greater when calculated with haplotype versus single SNPs as there is a 
lesser need for correction due to multiple testing (Clark 2004). The association between 
different haplotypes and disease risk can be calculated for instance with The HaploView 
program (www.broad.mit.edu/mpg/haploview) (Barrett 2009).  
 
2.2.1.2 Genome wide association study and meta-analysis 
In a GWAS, typically thousands to millions common variants, selected based on LD 
structure and using HapMap data sets (hapmap.ncbi.nlm.nih.gov/) (International HapMap 
Consortium 2005) for SNP selection, are genotyped using large population size (Marian 
2012). The genotyping is performed on a microarray platform with strict significance levels 
(p < 1 x 10-7). The choice of statistical significance threshold is important as if it is set too 
high, this may lead to the blending of true associations with the background and a loss of 
sensitivity, whilst lowering it would lead to the likelihood of more false positive findings 
(McCarthy et al. 2008). A correction for multiple testing (at least one test for each tested 
SNP) is needed to diminish false positive findings (Richards et al. 2015). As population size 
needed to ensure power in multiple testing grows, the phenotypic heterogeneity increases, 
causing possible simultaneous power reduction. This further emphasizes the need to match 
patients and controls stringently (McCarthy et al. 2008). Careful matching of patients and 
controls for demographic and other characteristics enrich the chance of detecting genetic 
effects and genetic isolates are in that sense preferable (Marian 2012). One other approach 
to manage population size and heterogeneity issues is a tiered design, where SNPs found to 
be significant in large population size GWAS are genotyped again repeatedly in a 
replication set always selecting only significantly associated SNPs for the next set. This 
eliminates false positive SNPs from the sets one by one. (Hoover 2007) 
As the ORs of the common variants associated with the disease found in GWAS are low in 
general with an average of 1.33 (Hindorff et al. 2009), it is hard to establish the functional 
basis and the contribution to the disease etiology solely with this method (Bodmer & 
Bonilla 2008) and the analysis of rare variants is still needed. When a new susceptibility 
locus has been found in GWAS, the possible effects of coding and non-coding SNPs in the 
candidate gene region must be evaluated (Coassin et al. 2010). The locus should be screened 
for genetic variations and mutations via sequencing (Maher 2008) and relevance of found 
mutations to disease progression should be studied further (Coassin et al. 2010).  
Another method to overcome problems with small population sizes is meta-analysis. Meta-
analysis is a method to quantitatively synthesize data across several independent studies. 
Summary ORs and 95% confidence intervals (CI) of allele or genotypic distributions in 
patients and controls in each population are calculated to reveal contrast between minor 
and major alleles or genotypes from at least four independent case-control samples. If study 
raw data are available, the data can be pooled and re-analyzed as a combined population. 
The risk of false positives can be diminished with procedures to discover possible biases 
like deviations in Hardy Weinberg equilibrium (HWE). (Bertram & Tanzi 2008) 
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Imputation methods can also be utilized in GWAS and meta-analysis studies. Sometimes 
combined data from collected datasets is not consistent and some genotype data is missing 
(Marchini et al. 2007). There are imputation softwares like IMPUTE (Marchini et al. 2007) 
and MACH (Li et al. 2010) that can estimate genotype and haplotype probabilities for the 
SNPs missing in the subgroup of datasets using HapMap data as reference. Imputation 
analysis thus enhances the power of the whole study group association studies (Li et al. 
2010). 
 
2.2.1.3 Transcriptomics based association studies 
Vast amount of genes have been found to undergo alternative splicing in human brain 
tissues (Wang et al. 2008). According to recent GWAS studies, gene expression regulation 
has been suggested to be a major modulator in AD progression instead of straight protein 
coding changes (Ramasamy et al. 2014, Visscher et al. 2012).  
A transcriptomics based association study is a high-throughput method that involves the 
measurements of traditional differential gene expression analysis (Zhang et al. 2013) using 
microarray ribonucleic acid (RNA) expression chipsets in certain cell cultures or tissue 
samples. Correlation of these levels to different SNP genotype or allele carrier status can 
then be calculated (Wes et al. 2015). If there are significant differences in expression levels 
between SNP genotype or allele carriers, it is possible that those gene variants some way 
affect transcriptional efficiency. When studying AD genetics, one should also keep in mind 
the possibility for some expression levels to differ between patients and controls due to 
pathologic changes in AD progression that would lead to altered expression and thus be a 
result and not a cause of the disease (Wes et al. 2015). Gene variants found to be associated 
with expression level changes are called expression Quantitative Trait Loci (eQTLs) (Wes et 
al. 2015).  This type of data can be used to localize causal risk genes in an associated region 
of several genes found in, for instance, GWAS studies (Ramasamy et al. 2014). 
 
 
2.2.1.4 Epigenetics in AD risk 
Epigenetics is concerned with evaluating the effect of long-term, but modifiable by external 
factors, heritable alterations that are not caused by physical changes to the order of 
nucleotide sequences in DNA (Wes et al. 2015). For instance, whilst DNA is wrapped into 
chromatin with proteins, the histones can be covalently modified and these changes can 
regulate gene expression (Tessarz & Kouzarides 2014). Epigenetic regulation also includes 
DNA methylation (on cytosine bases of CpG dinucleotides, not causing an immediate 
change to the sequence of the nucleic acid) of gene regulatory elements such as promoters, 
enhancers and repressors (Wes et al. 2015). New methods have been recently developed to 
map histone modifications and protein-DNA (deoxyribonucleic acid) interactions at the 
genome scale (Garber et al. 2012, Blecher-Gonen et al. 2013). These genome-wide epigenetic 
studies have been named as EWAS, Epigenome wide Association Studies (Wes et al. 2015).  
Recent EWAS studies have suggested that there might be as strong or even stronger 
association between epigenetic regulation of genes and AD risk than between DNA 
variants and AD risk (De Jager et al. 2014, Lunnon et al. 2014). A recent study with 
monozygotic twins with one twin having AD and the other not has found diversed 
epigenetic alterations in persons with the same genome leading to different outcome 
(Mastroeni et al. 2009). More studies are needed to further evaluate the heritability of AD 
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and to understand the complex co-operation of genetic variants, epigenomics, 
transcriptomics and proteomics in the risk and progression of AD. 
 
2.2.2 AD risk genes 
 
2.2.2.1 Causative disease causing mutations in AD 
There are rare, autosomal-dominant forms of EOAD caused by mutations in genes APP, 
PSEN1 and PSEN2 (Karch et al. 2014). APP encodes a versatile transmembrane protein, 
whose structure depends on alternatively spliced transcripts APP695, APP751 and APP770 
(Karch et al. 2014). Gene mutations in APP associated with AD have been shown to either 
increase the amount of β-amyloid peptides in general (Mullan et al. 1992, Guerreiro et al. 
2012) or promote the pathogenic cleaving process of APP (Bergmans & De Strooper 2010, 
Chavez-Gutierrez et al. 2012) which both cause the accumulation of β-amyloid in the brain. 
PSEN1 and PSEN2 encode sequences that translate into highly related membrane proteins 
with several transmembrane domains that are components of the APP -cleaving -secretase 
complex. Mutations in PSEN1 and PSEN2 have been found to either cause EOAD or 
increase the risk of EOAD depending on the mutation type (Guerreiro et al. 2012). Some of 
these mutations have also been found to be associated with the risk of the late onset AD 
(Cruchaga et al. 2010, Benitez et al. 2013). 
Rare variants of the gene ADAM10, which encodes an enzyme with a major APP targeting 
-secretase cleavage activity (Jorissen et al. 2010), have been recently found to increase A  
levels in vitro and to cosegregate genetically in a few AD families (Kim et al. 2009b). These 
variants disrupt -secretase function and lead to pathogenic A  peptide formation (Suh et 
al. 2013).  
All above mentioned variants that have been found to cause AD pathology, alter the 
production of A  peptide, causing it to accumulate in senile plaques (Guerreiro et al. 2012) 
which further emphasizes the role of β-amyloid metabolism in AD progression (Karch et al. 
2014). 
 
2.2.2.2 Common AD related variants 
The minor allele frequencies (MAFs) in the study population determine if the genetic 
variant is common (MAF > 5%), infrequent (MAF 1-5%) or rare (MAF < 1%) (Marian 2012).  
The power of statistical tests will diminish if there are low-frequent mutations at different 
sites in the gene, as surrounding SNPs that are in LD with the mutations show association 
with the disease (Pritchard 2001). The common disease common variant (CDCV) 
hypothesis claims that the common variants have a low ‘penetrance’ for the disease 
expression in the individuals but still represent a major contribution to the disease risk. In 
most cases, the disease associated common variant itself is usually unlikely to be 
functionally relevant, but it is in LD with a more rare functionally relevant variant (Bodmer 
& Bonilla 2008, Gorlov et al. 2008). These common variants affect disease risk typically only 
with an OR 1.1-1.4 as the common variants with higher ORs may have been subject to 
natural selection and thus occur only as rare variants (Bodmer & Bonilla 2008). With ORs 
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this low there must be a sufficient number of patients and controls to ensure the statistical 
significance of suspected SNP association with the disease.  
The common disease rare variant (CDRV) hypothesis, on the other hand, claims that the 
rare variants have a high ‘penetrance’ and are the major contributors to the disease risk 
(Schork et al. 2009). As rare variants are shown to be more likely functional than common 
variants (Gorlov et al. 2008) it has been proposed that these variants are new and have 
emerged after rapid expansion of human population and have not yet been subject to 
marked natural selection even with deleterious effects on the individual health (Pritchard 
2001). GWAS studies with common variants have managed to explain only around 10-15 % 
of disease heritable factors in general which points out that CDCV hypothesis alone cannot 
explain the heritability of complex diseases and that CDCV and CDRV hypothesis should 
be combined to achieve more comprehensive results (Maher 2008). 
Recent GWAS studies and meta-analysis methods have revealed several AD risk associated 
genes (Figure 6). These genes can be divided into groups based on their involvement in 
APP or tau metabolism, cholesterol metabolism, immune response, endocytosis, axon 
development, epigenetics or yet unknown mechanism (Karch & Goate 2015). 
 
Figure 6. Rare and common variants contribute to Alzheimer’s disease risk. (Reproduced from 
Karch & Goate, 2015, Biological psychiatry 2015;77:43-51, with the kind permission of 
Elsevier).  
 
 
Only few genes (ADAM10 and APOE) exhibit variants with medium or high risk of AD 
excluding the causal genes PSEN1, PSEN2 and APP.  In contrast, most of the common 
variants of genes ABCA7, CLU, CR1, CD33, CD2AP, EPHA1, BIN1, PICALM, MS4A, CASS4, 
CELF1, DSG2, FERMT2, HLA-DRB5-DBR1, INPP5D, MEF2C, NME8, PTK2B, SLC24H4-
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RIN3, SORL1 and ZCWPW1 show only modest OR variation (Karch & Goate 2015). Earlier 
found AD risk genes evaluated with meta-analyses include ACE, CH25H, CHRNB2, CST3, 
GAB2, LMNA, MAPT, PRNP and TF (Bertram & Tanzi 2008). In addition to these, there are 
numerous genes that have been found to have statistically significant associations with AD 
risk in smaller populations that are not mentioned here.   
 
2.2.3 Cholesterol metabolism genes in AD 
 
Cellular cholesterol is synthesized via the HMGCoA reductase pathway or transported 
from extracellular space via LDLR-APOE complex and exhibits either in cholesterol or 
cholesterol ester form (Bhattacharyya & Kovacs 2010). Brain cholesterol homeostasis is 
essential for many processes like signal transduction, myelin formation, synaptogenesis 
and membrane trafficking (Pfrieger 2003). Cholesterol metabolism has also been shown to 
closely interact with AD pathology as production and clearance of A  has been shown to be 
regulated by this compound (Bertram & Tanzi 2008).  
Cholesterol metabolism genes represent one major group of genes found to be associated 
with AD risk in previously performed GWAS and meta-analysis studies (Kalvodova et al. 
2005, Bertram & Tanzi 2008, Karch & Goate 2015, Liu et al. 2014) and also in several 
independent smaller studies. Genes APOE, CLU, ABCA7 and SORL1 are all mediators in 
cholesterol homeostasis and have been found significantly associated with AD risk in 
recent GWAS studies. 
APOE is the strongest risk factor found in AD (Karch & Goate 2015). It is involved in 
cholesterol transport, neuroplasticity and inflammation processes in the brain (Kim et al. 
2014). The APOE gene naturally occurs in the human population as three alleles ( 2, 3 and 
4) of which 4 has been highly significantly and dose dependently shown to be associated 
with increased risk of AD, earlier onset of AD and AD related neuropathology (Corder et 
al. 1993b, Kok et al. 2009). In contrast, the 2 allele associates with a decreased risk of AD 
and later age of onset (Corder et al. 1993a). Clusterin (CLU) is an apolipoprotein (encoded 
by the ApoJ gene) that can interact with A  and influence β-amyloid fibril formation (Oda et 
al. 1995, Kok et al. 2011). CLU mRNA expression has been found to be elevated in AD 
brains (Karch et al. 2012). ATP-binding cassette transporter A7 (transcribed from the human 
ABCA7 gene) is a transmembrane transporter which stimulates cholesterol efflux and 
inhibits A  secretion via increasing phagocytosis of A (Jehle et al. 2006) In addition to 
genes mentioned before in this chapter, sortilin-related receptor gene (SORL1) may also be 
associated with AD risk (Meng et al. 2007). It has been proposed that under-expression of 
SORL1 may increase A load in the brain (Rogaeva et al. 2007). 
In addition to GWAS studies, meta-analyses and association studies have revealed some 
other cholesterol metabolism associated candidates for risk gene case-control studies: LDLR 
is a receptor that binds cholesterol (Defesche 2004) and the APOE protein (Raussens et al. 
2002) as well as directly takes part in the clearance of A (Basak et al. 2012b)  Seladin-1, 
encoded by gene DHCR24, is a cholesterol synthesizing enzyme that has been shown to 
protect cells against A  mediated toxicity (Greeve et al. 2000) and take part in formation 
of cholesterol rich DRMs (Crameri et al. 2006). Cholesterol can bind to APP -secretase 
cleavage site in DRMs and when abundant, enhance pathogenic A  formation (Yao & 
Papadopoulos 2002). A  in turn can affect cholesterol binding to APOE (Yao & 
Papadopoulos 2002). LDLR shuttles cholesterol from extracellular space to cell membranes 
and into cell (Defesche 2004). APP and A have been shown to metabolize cholesterol to 7-
hydroxycholesterol (Nelson & Alkon 2005) which SOAT1 in turn metabolizes into 
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cholesterol esters (Zhang et al. 2003) and modulates A  production via 
cholesterol/cholesterol ester ratio (Puglielli et al. 2001, Colell et al. 2009) (Figure 7).   
 
 
Figure 7. Model of regulation of Aβ peptide production by cholesterol and sphingolipids. Under 
normal conditions, APP and β-site APP cleaving enzyme 1 (BACE1) are distributed in both DRMs 
(dark grey) and phospholipid domains (light grey) leading to non-amyloidogenic processing. 
Elevated cholesterol levels, activity of SOAT1 and LDLR related protein (LRP) all increase DRMs 
leading to amyloidogenic processing. (Reproduced from Colell et al., 2009, Journal of 
Bioenergetics and Biomembranes 2009;41:417-423, with the kind permission of Springer).  
 
As gene products of LDLR, SOAT1 and DHCR24 all take part in cholesterol homeostasis 
and β-amyloid metabolism in the brain, they are excellent candidates for association studies 
concerning AD risk and also AD CSF biomarker levels. 
 
2.2.3.1 Low density lipoprotein receptor (LDLR) 
LDLR binds APOE and transports cholesterol (Phillips 2014, Lopez et al. 2014) in the brain. 
Both APOE and cholesterol metabolism have been found to be associated with brain 
amyloidosis and AD risk (Puglielli et al. 2001, DeMattos et al. 2004, Bell et al. 2007, 
Huttunen et al. 2007). LDL cholesterol load in lipid rafts has been proposed to affect the 
activity of -secretase, which in turn cleaves APP and produces pathogenic A  peptides 
leading to accumulating of senile plaques (Kalvodova et al. 2005). In addition, LDL 
cholesterol load in blood and CSF has been found to correlate with A accumulation in the 
brain (Refolo et al. 2000). On the contrary, overexpressing of LDLR has been shown to 
decrease brain APOE levels and lead to a marked reduction of A  aggregates and 
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neuroinflammatory responses (Kim et al. 2009a) in transgenic mice. This LDLR induced 
enhanced clearance and uptake of A has been recently (Basak et al. 2012a) shown to be an 
APOE independent function where LDLR can directly bind A  These pathogenic processes 
all have LDLR as a modulator which raises a question whether variants in LDLR gene 
[GeneID: 3949, gi: 1683193] have association with AD risk and with progression of β-
amyloid plaques. 
LDLR gene locus 19p13.2 on the short arm of chromosome 19 has previously been shown to 
be associated with AD risk (Wijsman et al. 2004). Association studies performed with SNPs 
have shown that certain LDLR genotype and haplotype carriers may have an elevated risk 
of AD (Cheng et al. 2005, Gopalraj et al. 2005) found in combined group of males and 
females. Some studies, on the contrary, have not found any relation between LDLR variants 
and AD risk (Lendon et al. 1997, Rodriguez et al. 2006). Interestingly, earlier studies have 
implied that there is a gender specific effect of LDLR polymorphisms that may impact 
blood cholesterol levels (Ahn et al. 1994, Gudnason et al. 1995, Zhu et al. 2007) or splicing of 
the LDLR mRNA (Zhu et al. 2007, Zou et al. 2008). One study claims to have found a gender 
specific effect of LDLR polymorphisms also on AD risk (Zou et al. 2008). In summation, 
LDLR has an important role in cholesterol homeostasis, binding of APOE and clearance of 
A in the brain and is an interesting candidate for association studies. 
 
2.2.3.2 Sterol O-acyltransferase 1 (SOAT1) 
Sterol O-acyltransferase 1, also known as acyl coenzyme A:cholesterol acyltransferase 1 
(with the alternative gene name, ACAT1) is coded by gene SOAT1 [gene ID: 6646, gi: 
49533616] in chromosome 1. SOAT1 forms cholesterol esters from 7-hydroxycholesterol in 
the endoplasmic reticulum (Puglielli et al. 2001) and prevents the buildup of cholesterol in 
membranes (Bhattacharyya & Kovacs 2010). The intracellular cholesterol/cholesterol ester 
ratio has recently been proposed to impact APP cleavage and A production in the brain 
(Bryleva et al. 2010). Earlier studies have shown that blocking SOAT1 decreases A load 
both in cell culture and mouse models (Puglielli et al. 2001, Hutter-Paier et al. 2004, 
Huttunen et al. 2010) and SOAT1 blocking procedures have thus been suggested for 
treatment of AD (Bhattacharyya & Kovacs 2010). 
SOAT1 gene polymorphisms have previously been indicated to be associated with levels of 
plasma cholesterol binding ApoAI in males (Klos et al. 2006) and thus possibly affect 
A clearance (Paula-Lima et al. 2009, Lefterov et al. 2010) in the brain via reduced ApoAI 
levels in the brain (Kuriyama et al. 1994, Kawano et al. 1995, Merched et al. 2000). There are 
some older studies that have found significant associations between SOAT1 SNPs and AD 
risk in general (Wollmer et al. 2003, Papassotiropoulos et al. 2005) and some that have not 
reached significant findings (Zhao et al. 2005, Blomqvist et al. 2006). One study claims to 
have found a significant association between SOAT1 SNPs and β-amyloid load in healthy 
controls (Wollmer et al. 2003). And finally, a recent GWAS performed with gene 
enrichment analysis found SOAT1 polymorphisms to be significantly associated with AD 
risk (Jones et al. 2010). Regarding the essential role of SOAT1 in cholesterol homeostasis 
and thus the APP cleavage process as well as the recent genetic association study findings, 
SOAT1 is an interesting candidate gene for AD risk studies. 
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2.2.3.3 24-dehydrocholesterol reductase (DHCR24) 
Seladin-1 protein is encoded by the DHCR24 gene [gene ID: 1718, gi: 20141421] that resides 
in human chromosome 1. Seladin-1 synthesizes cholesterol (Waterham et al. 2001) and 
protects cells from oxidative stress (Greeve et al. 2000, Wu et al. 2004). Seladin-1 expression 
levels have been shown to decrease in AD affected neurons (Greeve et al. 2000, Iivonen et 
al. 2002) and affect DRM formation (Ledesma et al. 2003) and also activity A 42 degrading 
enzyme plasmin (Ledesma et al. 2000). It has also been discovered that downregulation of 
seladin-1 increases the level of -secretase in the cell and thus enhances the cleavage of APP 
to pathogenic Aβ peptide (Sarajärvi et al. 2009). Therefore, because of the role of seladin-1 
in β-amyloid homeostasis, DHCR24 is a good candidate gene for a case-control association 
study. 
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3 Aims of the study 
 
The goal of this thesis was to elucidate possible AD-related risk genes in a case-control 
association study setting, as well as to evaluate AD CSF biomarker levels between carriers 
of different alleles, genotypes and haplotypes. These studies focused on genes that have an 
important role in brain cholesterol homeostasis and β-amyloid metabolism.  
 
 
The specific aims were as follows: 
1. To study a possible genetic association between LDLR and AD risk and levels of AD 
CSF biomarkers A 42, tau and ptau in relation to different allele, genotype and 
haplotype carriers (Study I). 
2. To evaluate the possible genetic association between SOAT1 and AD risk and 
estimate levels of AD CSF biomarkers A 42, tau and ptau in relation to different 
allele, genotype and haplotype carriers (Study II). 
3. To elucidate the possible genetic association between DHCR24 and AD risk as well 
as to estimate allele, genotype and haplotype carriers’ levels of AD CSF biomarkers 
A 42, tau and ptau (Study III). 
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4 Subjects, materials and methods 
4.1 AD PATIENTS AND CONTROLS 
 
All AD patients and controls were examined in the Department of Neurology, Kuopio 
University Hospital and originated from eastern Finland. The subjects were asked for an 
informed consent and the Kuopio University Hospital ethics committee approved the 
study. The AD patients fulfilled the criteria of probable AD according to the NINCDS-
ADRDA criteria (McKhann et al. 1984). The subjects who were found to be neurologically 
intact were designated as controls. At the time of the cognitive evaluation the control group 
showed no signs of dementia on neuropsychological testing or interview. A subgroup 
(n=67) of AD patients were screened for known mutations in APP, PSEN-1 and PSEN-2 and 
no recognized mutations were found.  A positive family history of AD was found in one 
third of all AD patients, but there was inconclusive evidence for autosomal dominant 
transmission. The study group details for each study are shown in Table 1.  
 
 
Table 1. Age and gender of AD patients and controls in the three separate studies. 
Study AD patients Controls 
Age Male Female Age Male Female 
(Years) (n) (n) (Years) (n) (n) 
Study I (LDLR) 71.6±7.3 127 278 69.6±5.1 185 278 
Study II (SOAT1) 71.8±7.4  125 285 69.7±5.1 182 273 
Study III (DHCR24) 71.8±7.4  125 289 69.6±5.1 186 274 
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4.2 GENOTYPING 
 
In the three separate studies four to six SNPs (Table 2) were selected for each gene to cover 
the entire gene and locating either on the non-coding or coding regions. The SNPs were 
selected from Applied Biosystems (http://www.appliedbiosystems.com/) database using 
SNPbrowser™ 2.0 and 3.0 software. The DNA samples were isolated from blood with 
Blood Prep™ Chemistry kit (Applied Biosystems, Foster City, CA) and genotyping was 
performed using TaqMan Allelic Discrimination Assays (Applied Biosystems, Foster City, 
CA). The TaqMan genotyping reaction was done on a Research Peltier Thermal Cycler 
(PTC-200) with following cycling conditions: One cycle at 50°C for 2 min to activate uracil-
N-glycosylase, which is added to prevent carryover contamination, 95°C for 10 min to 
activate the AmpliTaq Gold Polymerase, 92°C for 15 s for denaturing, 60°C for 1 min for 
annealing and extending 39 times and finally cooling to 4°C for storage. The fluorescence 
was detected on an ABI Prism 7000 sequence detector (Applied Biosystems, Foster City, 
CA). 
 
Table 2. Single nucleotide polymorphisms, alleles and haplotypes used in three separate 
studies. 
 
Study   SNP Allele Haplotype 
          
Study I (LDLR)   rs11668477 A/G   
  rs12983082 C/A   
        
  rs11669576 G/A 
GCC/GCT/GTT/ATT   rs2738444 C/T 
  rs5925  C/T 
        
  rs1433099 C/T   
          
Study II (SOAT1)   rs2247071 C/T   
  rs2862616 C/T   
        
  rs3753526  C/G 
CA/CC/GA 
  rs1044925  A/C 
          
Study III (DHCR24)   rs638944 G/T 
GT/TC/GC/TT 
  rs600491 C/T 
        
  rs718265 A/G 
GC/AC/GT/AT 
  rs7374 C/T 
 
 
The LDLR SNPs are proximately 2.6 - 22 kb apart from each other and cover areas of the 
gene that represent the following protein product structures: ligand binding domain, EGF 
precursor homology domain and cytoplasmic domain (Figure 8).  
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Figure 8. A schematic diagram showing the structure of the LDLR gene in the chromosome 19 
and the SNPs used in the study. rs number= reference SNP cluster ID number; black vertical 
box=exon; horizontal lines=introns or non-coding area; EGF=Epidermal Growth Factor; 
Distances (kB) between exon 1 and exon 18 or between rs11668477 and rs1433099. 
 
 
The SOAT1 SNPs cover the non-coding and untranslated regions of the gene (Figure 9). 
 
Figure 9. A schematic diagram showing the structure of SOAT1 gene in the chromosome 1 and 
single nucleotide polymorphisms used in the study.  The dash lines show the approximate sites 
of SNPs in the gene. The distances between adjacent SNPs and the whole gene are given 
between two headed arrows. Lines represent the introns between exons (vertical boxes).  
Reference cluster ID (rs) of SNPs is given above the dash lines and the major and minor allele 
identity of every SNP used in the study is shown under the rs numbers. 
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The DHCR24 SNPs locate on the coding region of the gene and are on average 3.6 - 13.6 kb 
apart from each other (Figure 10). APOE genotype was previously determined for the AD 
patients and controls by the standard method (Lehtovirta et al. 1996). 
 
 
Figure 10. A schematic diagram showing the structure of DHCR24 gene in the chromosome 1 
and single nucleotide polymorphisms used in the study. 
 
4.3 CSF BIOMARKER ANALYSIS 
 
A lumbar puncture was used to collect CSF samples from the subgroup of AD patiens and 
controls for biomarker analysis (Table 3) and the samples were stored in polypropylene 
tubes at -70 °C. The CSF levels of A 42, tau and phosphorylated tau (ptau) were measured 
by an ELISA method (Innogenetics, Ghent, Belgium) according to the manufacturer's 
instructions. Samples were in addition blinded to the diagnosis to avoid bias. 
 
Table 3. Age and gender of AD patients and controls with CSF available for biomarker analysis 
in the study series. 
Study AD patients Controls 
Age Male (n) Female (n) Age Male (n) Female (n) 
Study I (LDLR) 74.5±9.5 13 68 68.6±4.2  3 7 
Study II (SOAT1) 71.9±9.2 5 39 68.5±4.1 3 7 
Study III (DHCR24) 71.9±9.2 5 39 68.5±4.1 3 7 
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4.4 STATISTICAL ANALYSIS 
 
The GenePop program (http://wbiomed.curtin.edu.au/genepop/genepop_op1.html) was 
used to calculate Hardy-Weinberg equilibriums for of SNPs in AD patients and controls. 
SPSS software 11.5.1 (IBM SPSS Statistics, USA) was used for calculating allele and 
genotype frequencies with Pearson's χ2 test and Fisher's exact test. The global significance 
of the haplotype distribution was calculated with Pearson's χ2 test. The means of CSF 
biomarker levels between the genotype groups were compared with the non-parametric 
Kruskal-Wallis test and the non-parametric Mann-Whitney test for comparing biomarker 
levels between two genotype groups (one group pooled e.g. CT/TT vs. CC). The HaploView 
program (www.broad.mit.edu/mpg/haploview) was used to calculate pairwise LD values 
and to estimate haplotypes. The estimation of biomarker levels in haplotype carriers was 
performed with Thesias program which uses the Stochastic-EM algorithm for statistical 
analysis (http://genecanvas.ecgene.net/downloads.php?cat_id=1). Power calculations were 
carried out using the Genetic Power Calculator (Purcell et al. 2003). The level of statistical 
significance was set at p ≤ 0.05.  
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5 Results  
5.1 ASSOCIATION OF LDLR GENE WITH THE RISK OF AD AND ITS CSF 
BIOMARKERS 
 
LDL receptor coding gene LDLR is located in chromosome 19 which has been shown to be 
associated with AD risk (Wijsman et al. 2004). In previous association studies LDLR SNPs 
were associated with AD risk in Caucasians either with a coexisting APOE 4 allele or as a 
haplotype (Cheng et al. 2005, Gopalraj et al. 2005).  We wanted to elucidate whether there is 
an association between LDLR SNPs and AD occurrence in our population as well and 
whether there is any difference in CSF tau, phosphorylated tau or A  peptide levels 
between different genotype and haplotype carriers. We genotyped LDLR SNPs rs11668477, 
rs12983082, rs11669576, rs2738444, rs5925 and rs1433099 and evaluated the APOE 4 allele 
carrier status in 405 Finnish AD patients and 463 controls.  
As expected, we found that the APOE genotype distribution differed between 405 AD 
patients and 463 controls (p < 0.001) so that the AD patients carried the 4 allele seven-fold 
more likely than the controls (OR 7.2 95% CI 5.4-9.7). The AD patients carrying the 4 allele 
were also significantly younger than the 4 that did not carry a copy of this allele (71.2 years 
versus 73.5 years; p = 0.005). We then studied the distribution of single SNP genotypes of 
LDLR gene in the whole study group and found no significant difference between patients 
and controls. On the other hand, stratification according to age of onset, APOE 4 allele 
carrier status and gender revealed that in contrast to men,  the T allele of rs2738444 was 
overrepresented in AD females (OR 1.6 95% CI 1.1.-2.3 p = 0.014).  However if we use 
Bonferroni correction and correct with the number of tests (n = 18), the association of this 
SNP with AD risk fails to reach the level of statistical significance (p < 0.05). In contrast to 
previous studies (Cheng et al. 2005, Gopalraj et al. 2005) we found that using the logistic 
regression model between the study groups, APOE 4 allele carrier status or age of onset 
did not significantly modify the risk between T allele of rs2738444 and AD. We though 
found a synergic effect of female gender and the T allele of rs2738444 which caused these 
two parameters to interact and increase the AD risk (OR 2.6 95% CI 1.3-4.9 p = 0.005, 
Bonferroni corrected p = 0.090). 
Next we used the HaploView program to find possible haplotypes and found strong 
pairwise LD (D’ values between 0.8 and 1) between SNPs rs12983082, rs11669576, 
rs2738444, rs5925 and rs1433099. Haplotype estimation revealed one haplotype block (Table 
2) consisting of markers rs11669576, rs2738444 and rs5925. We found that in females the 
overall haplotype distribution differed significantly between patients and controls and that 
the specific haplotype GTT was overrepresented in AD females (0.103) compared to control 
females (0.060) (Table 4) due to inclusion of the T allele of rs2738444 in this haplotype. In 
contrast, the haplotype GCT was significantly underrepresented in AD females (0.324) 
compared to control females (0.381). 
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Table 4. Estimated haplotype frequencies in haploblock SNPs and case–control frequency ratios 
in all and in males and females separately. 
 
                      
Haplotype Whole study group Males Females 
  Frequency 
n = 1736 
AD n = 810, 
control        
n = 926  
p 
value 
  Frequency 
n = 624 
AD n = 254, 
control       
n = 370 
p 
value 
  Frequency 
n = 1112 
AD n = 556, 
control       
n = 556  
p 
value 
GCC 0.519 
0.517, 
0.522 0.820 0.537 
0.531, 
0.542 0.783 0.510 
0.511, 
0.509 0.955 
GCT 0.340 
0.333, 
0.347 0.525 0.318 
0.351, 
0.296 0.146 0.353 
0.324, 
0.381 0.044 
GTT 0.089 
0.096, 
0.083 0.337 0.103 
0.082, 
0.118 0.150 0.081 
0.103, 
0.060 0.008 
ATT 0.048 
0.048, 
0.047 0.954 0.037 
0.028, 
0.043 0.307 0.054 
0.057, 
0.050 0.600 
  Overall p = 0.141     Overall p = 0.141     Overall p = 0.015   
Haplotype consist of SNPs rs11669576, rs2738444 and rs5925. n = number of alleles; p values are calculated with 
Pearson χ2 method. 
 
 
In AD a marked, age-independent decline in the CSF A levels (Sjogren et al. 2001) and 
increased CSF tau and ptau levels are taken as surrogate biomarkers of evidence of axonal 
damage and neuronal degeneration in the brain (Hampel et al. 2004). As we found out that 
certain alleles, genotypes and haplotypes are overrepresented in AD females, we next 
examined if there was a difference in CSF tau, ptau or A  peptide levels between different 
LDLR genotype and haplotype carriers. We measured CSF A tau and ptau levels from 
81 AD patients and 10 controls and found out that A levels were lower in the AD 
patients than controls (p < 0.001) and mean tau levels were higher in AD patients than 
controls (p = 0.021). AD patients that carried the APOE 4 allele (n = 51) had lower 
A levels than 4 non-carriers (p = 0.058) and significantly higher tau levels (p = 0.013) 
than 4 non carriers (n = 30). 
We observed that AD patients carrying rs12983082 AA or CA genotypes had significantly 
lower mean CSF A levels than the CC genotype carrier patients (Table 5). We also 
discovered that AD patients carrying rs5925 TT genotype had significantly higher mean 
CSF tau and ptau levels than CC or CT carriers. Despite the overall increased risk of AD 
found earlier in this study among rs2738444 T allele carrier females, we found no significant 
associations of rs2738444 genotypes with the levels of the biomarkers tested here.  
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Table 5. CSF Aβ42, tau and ptau measurements of different SNP genotype carriers in AD 
patients and controls. 
 
                  
SNP n AD patients n Controls 
    Aβ42 
(pg/ml) 
Tau 
(pg/ml) 
Ptau 
(pg/ml) 
  Aβ42 
(pg/ml) Tau (pg/ml) 
Ptau 
(pg/ml) 
rs11668477   
  AA 48 409 ± 130 538 ± 278 65 ± 30 7 670 ± 154 394 ± 102 74 ± 15 
  AG + GG 22 399 ± 86 564 ± 308 71 ± 16 3 1066 ± 230 282 ± 74 65 ± 15 
   p value  ns ns ns  ns ns ns 
   
rs12983082   
  CC 21 477 ± 118 488 ± 259 65 ± 25 5 678 ± 164 345 ± 69 66 ± 12 
  CA + AA 59 391 ± 144 583 ± 299 68 ± 31 5 900 ± 294 376 ± 140 75 ± 19 
   p value  0.003 ns ns  ns ns ns 
   
rs11669576   
  GG 71 406 ± 118 573 ± 300 68 ± 31 9 745 ± 226 367 ± 109 71 ± 16 
  GA + AA 8 383 ± 135 464 ± 180 61 ± 21 1 1179 ± 0 295 ± 0 74 ± 0 
   p value  ns ns ns  ns ns ns 
   
rs2738444   
  CC 53 412 ± 128 512 ± 249 62 ± 25 9 745 ± 226 367 ± 109 71 ± 16 
  CT + TT 27 394 ± 104 656 ± 342 77 ± 37 1 1179 ± 0 295 ± 0 74 ± 0 
   p value  ns ns ns  ns ns ns 
   
rs5925   
  CC + CT 60 407 ± 120 524 ± 286 64 ± 29 7 710 ± 145 353 ± 114 67 ± 15 
  TT 18 400 ± 111 697 ± 273 79 ± 31 3 972 ± 392 378 ± 100 81 ± 13 
   p value  ns 0.006 0.043  ns ns ns 
   
rs1433099   
  CC + CT 75 404 ± 121 563 ± 297 68 ± 30 9 745 ± 226 367 ± 109 71 ± 16 
  TT 4 409 ± 122 508 ± 172 ,60 ± 12 1 1179 ± 0 295 ± 0 74 ± 0 
   p value  ns ns ns  ns ns ns 
   
The values are given as mean ± S.D. The significance was tested with Mann-Whitney test. n = number of 
subjects; ns = non significant. 
 
 
 
As there was a significantly elevated risk of AD in haplotype GTT carrier females found 
earlier in the study, we used the Thesias program to estimate the mean levels of CSF 
A tau and ptau between different haplotype carriers in 69 AD patients. We found that 
the GTT haplotype was also significantly associated with elevated CSF tau and ptau values 
in AD patients (Table 6). On the other hand no associations with CSF A  levels and 
haplotypes were found in our study (data not shown). 
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Table 6. Estimated LDLR haplotypes with expected phenotypic mean of total and ptau values in 
AD patients. 
 
Haplotype Frequency Expected 
phenotypic mean 
95% CI p’ value Expected phenotypic 
adjusted mean 
95% CI Adjusted 
p* value 
Total tau 
  All (n = 138) 
    GCC 0.493 210.94 143.78–278.09 x 101.79 −73.28–276.87 x 
    GCT 0.304 304.66 216.69–392.63 0.135 201.24  −2.07–404.55 0.147 
    GTT 0.145 463.38 363.08–563.67 <0.001 322.74 118.11–527.36 0.007 
    ATT 0.058 178.99 −57.05–415.02 0.805   82.20 −217.68–382.08 0.881 
  Females (n = 112) 
    GCC 0.545 208.58 139.99–277.17 x 189.36   98.00–280.71 x 
    GCT 0.250 352.91 245.70–460.12 0.049 308.73 145.24–472.21 0.145 
    GTT 0.143 429.11 316.42–541.81 0.003 357.75 186.81–528.69 0.045 
    ATT 0.063 199.44 −38.30–437.17 0.945 186.30 −72.77–445.37 0.982 
  Males (n = 26) 
    GCC 0.269 168.67 −184.57–521.90 x 171.00 −236.88–878.88 x 
    GCT 0.538 224.67  36.85–412.48 0.792 226.00   8.87–443.12 0.801 
    GTT 0.154 619.33 314.37–924.30 0.152 622.50 70.16–1174.84 0.184 
Ptau 
  All (n = 138) 
    GCC 0.493 28.79 22.02–35.56 x 24.36 6.70–42.04 x 
    GCT 0.304 33.58 22.80–44.36 0.494 29.49 7.53–51.46 0.490 
    GTT 0.145 50.64 40.11–61.16 0.002 45.20 21.83–68.58 0.018 
    ATT 0.058 26.52   3.29–49.76 0.859 22.57 −7.08–52.22 0.889 
  Females (n = 112) 
    GCC 0.545 28.51 21.57–35.44 x 27.83 19.48–36.17 x 
    GCT 0.250 35.99 23.35–48.64 0.342 34.42 17.26–51.57 0.445 
    GTT 0.143 47.91 35.39–60.42 0.013 45.37 25.76–64.98 0.063 
    ATT 0.063 30.36   5.64–55.08 0.892 29.89   3.82–55.97 0.881 
  Males (n = 26) 
    GCC 0.451 28.63 −1.11–58.38 x 29.73 −7.37–66.84 x 
    GCT 0.329 27.85   9.37–46.33 0.970 28.45    6.02–50.88 0.953 
    GTT 0.183 74.89   48.79–100.99 0.062 76.43   36.28–116.57 0.061 
Haplotypes consist of SNPs in order of rs11669576, rs2738444 and rs5925. n = number of alleles; p' value is calculated with 
the Stochastic-EM algorithm using the most frequent haplotype GCC as reference (x); p* value is calculated with covariates 
gender and APOE ε4 carrier status. The haplotypes with frequency <0.05 are not shown. The haplotypes are calculated in all 
subjects and females and males separately. 
 
5.2 SOAT1 GENE AND THE RISK OF AD 
 
In AD β-amyloid plaques consisting of pathologically cleaved β-amyloid precursor protein 
affect the brain. SOAT1 forms cholesterol esters from cholesterol in the endoplasmic 
reticulum and has been found to regulate the production of β-amyloid precursor protein 
(Puglielli et al. 2001, Huttunen et al. 2009). Its inhibition has been found to reduce brain β-
amyloid plaques, insoluble β-amyloid levels and brain cholesterol esters in a transgenic 
mouse model of AD (Hutter-Paier et al. 2004). There are not so many studies considering an 
association between SOAT1 gene and AD risk (Wollmer et al. 2003, Papassotiropoulos et al. 
2005, Zhao et al. 2005, Blomqvist et al. 2006), so we decided to conduct a single allele and 
genotypic distribution comparison as well as estimate the haplotype frequencies between 
patients and controls. We also measured the level of CSF biomarkers in genotype and 
haplotype carriers in a subgroup of patients and controls. 
33 
 
 
We selected four SNPs; rs2247071, rs2862616, rs3753526 and rs1044925 and calculated the 
HWE in patients (n = 410) and controls (n = 455) using the GenePop program. As expected, 
all SNPs were in HWE in the controls implying that the genotyping was done correctly 
(Gomes et al. 1999). In AD patients the SNPs rs2247071 (p = 0.0008) and rs1044925 (p = 
0.0052) deviated from HWE with an excess of homozygotes (in order of CC and TT, AA and 
CC). We then calculated the allelic and genotypic distribution of SNPs in patients and 
controls. The distribution differences found failed to reach significance with Bonferroni 
correction. The rs2247071 CC was overrepresented in patients (OR = 1.4, 95% CI = 1.04-1.78; 
p = 0.029, Bonferroni corrected p = 0.348 with 12 tests) when compared to other genotypes. 
The logistic regression analysis revealed that the distribution difference found with 
rs2247071 CC was independent of gender, age or APOE 4 allele carrier status (OR = 1.4, 
95% CI = 1.01-1.89; p = 0.043, Bonferroni corrected p = 0.172 with 4 tests). In contrast, the 
three other SNPs showed no association with AD risk. 
Haplotype estimation revealed that SNPs rs2247071 and rs2862616 (D’ value 0.99), as well 
as SNPs rs3753526 and rs1044925 (D’ value 0.95), were strongly linked together in pairwise 
LD. According to the HapMap project (http://www.hapmap.org/index.html.en) there are 
three haplotype blocks in the SOAT1 gene with samples collected from US residents with 
northern and western European ancestry. The SNPs rs3753526 and rs1044925 exist in the 
same block in that population and we found that those two SNPs constitute a block also in 
our population. Despite the strong linkage between SNPs rs2247071 and rs2862616 the 
SNPs did not form a block in our study, possibly due to the 26.1 kb distance between them. 
The distribution of haplotypes consisting of the SNPs rs3753526 and rs1044925 did not 
differ significantly between patients and controls and no association between haplotypes 
and AD risk was found. 
We measured CSF biomarker levels of A tau and ptau from subgroup of patients (n = 44) 
and controls (n = 10) and compared them to the different allele and genotype carrier status 
of the individuals. No significant relations were found in comparison study. We also 
estimated the levels of biomarkers in all haplotype carriers but found no association 
between biomarkers and haplotypes either. 
5.3 ASSOCIATION OF DHCR24 GENE WITH THE RISK OF AD AND ITS 
CSF BIOMARKER LEVELS 
 
Seladin-1 is a cholesterol synthesizing enzyme (Waterham et al. 2001) which protects brain 
cells against oxidative and A -mediated toxicity (Greeve et al. 2000). In AD the 
expression level of seladin-1 is reduced in affected neurons (Iivonen 2005) and the DRMs, 
whom seladin-1 normally participates (Crameri et al. 2006) to organize, are disorganized 
(Ledesma et al. 2003). Disorganized DRMs lead to increased A formation (Abad-
Rodriguez et al. 2004) and accumulation of senile plaques (Hardy & Selkoe 2002). 
Despite the known association between seladin-1 and AD pathogenesis (Greeve et al. 2000, 
Iivonen 2005) there were no studies considering the genetic association of DHCR24 gene 
and AD when we decided to start investigate it in the Finnish population. Our goal was to 
estimate the possible genetic association of DHCR24 with AD risk and with levels of known 
CSF AD biomarkers A tau and ptau. To do so, we selected four SNPs (rs638944, 
rs600491, rs718265 and rs7374) that had high enough minor allele frequency to ensure 
power in calculations and genotyped them in 414 patients and 459 controls.  
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All DHCR24 SNPs were in HWE in patients and controls implying that the genotyping was 
done correctly (Gomes et al. 1999). We calculated the allelic and genotypic distribution of 
both patients and controls and found no significant association of any single SNPwith AD 
risk in the whole study group. Stratification according to gender, APOE 4 allele carrier 
status and age (data not shown), however, revealed that males carrying the T allele of 
rs600491 had a significantly increased risk of AD (OR 1.7 95% CI 1.2-2.4; p = 0.004, 
Bonferroni corrected p = 0.048 with 12 tests). Some of the found genotypic and allelic 
distribution differences failed to reach significance with Bonferroni correction. The 
genotype TT of rs600491 was overrepresented in male AD patients compared to male 
controls with p = 0.017, Bonferroni corrected p = 0.204 with 12 tests. The T allele of SNP 
rs7374 was on the other hand underrepresented (OR 0.7 95% CI 0.445-0.989; p = 0.043, 
Bonferroni corrected p = 0.516 with 12 tests) in AD men, but the genotypic distribution did 
not reach significance. 
We performed pairwise LD estimation on the DHCR24 SNPs in our study and found that 
rs638944 and rs600491 were strongly linked together (D’ value 0.79). The HapMap project 
with the samples from the U.S. residents with northern and western European ancestry 
showed that there are two haplotype blocks within the DHCR24 gene and that rs638944 and 
rs600491 are in one whereas rs718265 and rs7374 are in the other. Therefore, we estimated 
haplotypes of these two blocks (Table 7) in the whole study population. We found a highly 
significant overall haplotype block 1 distribution (p < 0.0001) between patients and controls 
and a specific haplotype TC which is underrepresented in AD patients compared to 
controls (p = 0.0002). We also found a risk haplotype GC (p < 0.0001). Stratification 
according to gender or APOE 4 allele carrier status did not change the haplotype 
distribution (data not shown). The block 2 haplotypes did not significantly differ between 
AD patients and controls.  
 
Table 7. The haplotype distribution of the haplotype blocks in the whole study group. 
 
    Frequency        
Haplotype Frequency  AD (n=828), Control  (n=918) Chi Square p value Overall p value 
Block 1 
    GT 0.627 0.605, 0.647 3.296 0.0695 
    TC 0.259 0.218, 0.296 13.726 0.0002 
    GC 0.073 0.103, 0.045 21.836 <0.0001 
    TT 0.042 0.074, 0.012 41.671 <0.0001 
     <0.0001 
Block 2 
    GC 0.579 0.584, 0.574 0.154 0.695 
    AC 0.183 0.181, 0.185 0.048 0.827 
    GT 0.179 0.179, 0.180 0.0030 0.956 
    AT 0.059 0.057, 0.061 0.139 0.709 
     0.959 
            
Haplotype Block 1 consists of SNPs rs638944 and rs600491. Haplotype Block 2 consists of SNPs 
rs718265 and rs7374. n = number of gametes. Single haplotype p value is calculated with Haploview 
program and overall p value with RxC program using metropolis algorithm. 
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We measured CSF A tau and ptau levels from a subgroup of AD patients (n = 44) and 
controls (n = 10) and estimated their association with DHCR24 polymorphisms. AD patients 
carrying the SNP rs718265 GG genotype had significantly lower level of A compared to 
AA and AG genotype carriers with p = 0.030 in the whole study group. This effect on 
A was seen in both males and females when calculated separately (data not shown). Tau 
or ptau levels did not differ between different genotype carriers (data not shown). 
Although there were highly significant differences in haplotype block 1 carriers among AD 
patients and controls, we found no association between different haplotypes and CSF 
biomarker levels.  
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6 Discussion 
6.1 LDLR GENE, AD RISK AND AD CSF BIOMARKERS 
 
We found that the T allele of rs2738444 was overrepresented in AD females but not in 
males, and this was independent of both APOE 4 allele carrier status and age of onset. We 
also found that in the female group a haplotype distribution consisting of markers 
rs11669576, rs2738444 and rs5925, differed significantly between patients and controls and 
the GTT haplotype was overrepresented in AD females compared to control females. A 
haplotype GCT was then found to be underrepresented in AD females compared to control 
females. Interestingly the risk haplotype GTT was significantly associated with elevated tau 
and ptau values in AD patients. When estimated separately in females and males, the 
association was still significant in females. AD patients carrying rs12983082 AA or CA 
genotypes had significantly lower mean CSF A levels than the CC genotype carrier 
patients. AD patients carrying the rs5925 TT genotype had also significantly higher mean 
CSF tau and ptau levels than CC or CT carriers.  
There are only few lipid metabolism genes that have reached a significant association in 
GWAS analysis with large population size. The LDLR gene is not one of them, although it 
has previously been found to be significantly associated with AD risk in smaller population 
samples (Kalvodova et al. 2005, Cheng et al. 2005, Gopalraj et al. 2005) and with the risk of 
dementia (mostly AD patients) (Reynolds et al. 2010). LDLR is located in the chromosomal 
locus proposed to be associated with AD (Wijsman et al. 2004) and the LDLR receptor can, 
in addition to transporting cholesterol, bind APOE (Phillips 2014, Lopez et al. 2014), which 
is a known genetic AD risk modulator. It has been also suggested that LDL cholesterol load 
(Kalvodova et al. 2005) in lipid rafts affect the activity of -secretase which is an APP 
cleaving enzyme and that LDLR straightly binds A  leading to A degradation in 
lysosomes (Basak et al. 2012a). Different LDLR genotype carriers may have a differing 
receptor capability towards transport cholesterol, involvement in signal transduction, 
ligand transport properties (Kivipelto et al. 2002) or lipid metabolism related protein 
expression levels that affect AD risk (DeMattos et al. 2004). 
Females have a higher risk of AD than males (Vina & Lloret 2010). AD progresses more 
rapidly in females than males (Holland et al. 2013, Pusswald et al. 2015) and females are 
more at risk to develop AD preceeding from MCI (Li et al. 2015, Ungar et al. 2014). It has 
also been proposed that the APOE 4 allele increases risk of AD more in females than males 
(Payami et al. 1996, Raber et al. 2002, Farrer et al. 1997). As LDL receptor binds APOE it is 
tempting to think that there are gender specific properties that may affect AD risk both via 
LDL cholesterol metabolism and A  clearance as well as via its effect on APOE metabolism. 
The same two LDLR polymorphisms that we used in our study have previously been found 
to be associated with blood lipid levels in a gender specific manner (Ahn et al. 1994, 
Gudnason et al. 1995). In a study performed by Gudnason and co-workers, males carrying 
the A allele of rs11669576 had higher blood cholesterol and apolipoprotein B levels than GG 
genotype carrier males but conversely females with the A allele had lower levels of these 
variables than the GG carriers (Gudnason et al. 1995). The rs5925 SNP was in another study 
(Ahn et al. 1994) found to be associated significantly with blood total cholesterol and LDL 
cholesterol levels in females.  
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In an earlier study with human postmortem brain samples and blood leucosytes collected 
from AD patients and controls, Zou and colleagues discovered that a common LDLR 
polymorphism rs688 modulated the mRNA splicing efficiency of LDLR exon 12 in elderly 
males but not in females. The rs688 TT genotype was significantly associated with AD risk 
in males and suggestively protective in females (Zou et al. 2008) implying a gender specific 
splicing of LDLR mRNA in the brain. On the contrary, the same polymorphism was found 
to modulate differentially mRNA splicing of exon 12 in female human liver and was 
associated with significantly higher LDL and total cholesterol in females, but not in males 
(Zhu et al. 2007). As there was an opposite effect on the rs688 polymorphism found in 
males and females, it is possible that the earlier studies that failed to find an association 
with other LDLR SNPs (Rodriguez et al. 2006, Lendon et al. 1997) in the whole study group 
might have seen different results if stratified genderwise. 
We did not have blood cholesterol values for neither our patients nor controls, so we could 
not estimate any possible link between blood cholesterol levels and the risk of AD in our 
population. The females in our study were of post-menopausal age, so there might be some 
kind of relationship between the decrease of estrogen and cellular uptake of cholesterol-
APOE complex (Raber 2004). Our finding that the risk haplotype GTT and the single SNP 
rs5925 were associated with higher tau and ptau levels independently of APOE 4 allele 
status may imply that LDLR gene polymorphisms may exert their effect on tau pathology 
via cholesterol metabolism. This may be due to an altered level of blood and CNS lipids or 
A , but this remains to be clarified. 
We found a gender specific effect of LDLR genotypes and haplotypes on AD risk which was 
independent of APOE 4 allele carrier status. In a stratification analysis APOE 4 allele was 
estimated to have an equal effect on AD risk in both males and females. Both genetic and 
biomarker analysis support the possibility that LDLR gene may be associated with AD risk 
and its CSF biomarkers, especially in females. 
We had a relatively small study population and when stratification was used, the 
possibility of false positives increases. To diminish this threat we used Bonferroni 
correction in our calculations and used haplotype estimation to increase the power in the 
genotype association analyses. The small group of patients and especially controls with 
known CSF biomarker levels diminished the power of the association analyses between 
CSF biomarkers and different haplotypes, especially when stratified with gender, as there 
were very few men in the subgroup. Despite of these assessment issues the gender specific 
association we found between LDLR genotypes and AD risk would make an interesting 
further study topic. The role of LDLR in cholesterol metabolism and affecting other blood 
lipid levels, in APOE metabolism and A  clearance and whether there is a gender specific 
LDLR mRNA splicing difference would further increase the knowledge of metabolism 
involved in AD progression. 
6.2 SOAT1 GENE AND AD RISK 
 
We genotyped four SOAT1 SNPs and all SNPs were in HWE in the control group implying 
that the genotyping was successful. On the other hand, the deviations can be expected 
(Wittke-Thompson et al. 2005) in the patient group or they can be even used as a tool to 
detect marker-disease association (Nielsen et al. 1998, Lee 2003, Oka et al. 1999). In our AD 
patients the SNPs rs2247071 and rs1044925 deviated from HWE due to an excess of 
homozygotes. We discovered that the genotype CC of SNP rs2247071 was significantly 
overrepresented in patients increasing the risk of AD. The result remained significant after 
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logistic regression analysis with correction for age, gender and APOE 4 allele carrier 
status. The strong deviance from HWE of the same SNP in the AD patients implies that the 
rs2247071 polymorphism may be in LD with some causal variation increasing the risk of 
the disease’s occurence (Weinberg & Morris 2003). We used haplotype estimation to 
evaluate possible haplotypes between SNPs and found that SNPs rs3753526 and rs1044925 
form a haplotype. Haplotype distribution did not differ significantly between AD patients 
and controls. We also measured CSF A tau and ptau levels from a subgroup of AD 
patients and controls but found no association between allelic, genotype or haplotype 
distribution in patients and controls and these biomarkers. 
The SOAT1 associated SNP rs2247071 has been suggested to be linked to plasma cholesterol 
binding lipoprotein ApoAI levels in white males (Klos et al. 2006) in a study focused on 
reverse cholesterol transport pathway in peripheral tissues. The level of ApoAI has been 
found to be decreased both in plasma (Kawano et al. 1995, Kuriyama et al. 1994, Merched et 
al. 2000) and brain (Puchades et al. 2003, Castano et al. 2006, Roher et al. 2009) of AD 
patients. As the plasma ApoAI has been shown to enter CNS via blood brain barrier (Stukas 
et al. 2014) and reduce A induced toxicity by binding A (Lefterov et al. 2010, Paula-Lima 
et al. 2009 , the decrease in the ApoAI levels may interfere with brains ability to fight 
neurodegeneration. Inhibition of SOAT1 has been proposed to promote atherosclerosis 
(Nissen et al. 2006, Meuwese et al. 2009) in humans which further implies that SOAT1 may 
affect plasma cholesterol levels via apolipoprotein particles. It is also noteworthy that in a 
gene enrichment analysis performed by Jones et al. (Jones et al. 2010) using the data 
acquired from a recent GWAS study (Lambert et al. 2009) the SOAT1 polymorphisms were 
found to be highly significantly associated with AD risk.  
SNP rs1044925 has been proposed to be associated with a reduced risk of AD (Wollmer et 
al. 2003) in the combined European population and a lower brain β-amyloid load in healthy 
controls. We had only 10 CSF control samples and it is possible that the proposed effect of 
rs1044925 on the CSF A levels could not be discovered or inspected critically due to the 
small sample size. It may also be that there is no significant association between genotypes 
of rs1044925 and AD CSF biomarker levels in the Finnish population. 
It is possible that the association we found between SOAT1 SNP rs2247071 and AD reflects 
the role of SOAT1 in cholesterol homeostasis and its association with apolipoprotein levels 
in brain. The fact that we did not find any allelic significance between AD patients and 
controls with any SOAT1 SNPs in our study suggests that there is no direct or strong 
association between SOAT1 polymorphisms and AD risk in our population.  SOAT1 may in 
that way be only a minor AD risk modulator and in addition be in linkage disequilibrium 
with an unknown genetic risk factor. 
6.3 DHCR24, AD RISK AND AD CSF BIOMARKERS 
 
We found that in contrast to the whole study group, males carrying the T allele of rs600491 
had a significantly increased risk of AD and that the genotype TT was overrepresented in 
AD males compared to control males. In addition, the T allele of rs7374 appeared as a 
protective allele in males with 0.7 –fold odds of AD compared with C allele carrier males. 
As there is a possibility of false positive observation when using stratification procedure, 
we used the Bonferroni correction for the possible problems associated with multiple 
testing and/or binary logistic regression model to estimate the effect of these variables. The 
risk effect of rs600491 T allele remained significant even after the Bonferroni correction was 
applied to the data.  In a later study replicating our study assessment in Hungarian 
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population (Feher et al. 2012) the genotype TT was similarly found to be significantly 
overrepresented in their cohort of AD males. 
We estimated the association between DHCR24 polymorphisms and CSF AD biomarker 
A tau and ptau levels in a small subgroup of AD patients and controls and found that 
AD patients carrying the SNP rs718265 GG genotype had significantly lower level of CSF 
A than AA and AG genotype carriers. There was no association between CSF tau and 
ptau levels and DHCR24 polymorphisms in our study, nor did we find any association 
between different haplotypes and CSF biomarker levels. As our biomarker study group 
was small and there were only 5 AD males and 3 control males in the group, it is possible 
that any effect in males would not have enough power to be seen in this study. 
The cumulative effect of haplotype consisting of several SNPs in LD with causal variation is 
easier to detect than the risk effect of a single SNP (de Bakker et al. 2005) and SNPs show 
more power when calculated together. Taking this into account we performed an haplotype 
estimation between AD patients and controls and discovered that distribution of block 1 
haplotypes consisting of the strongly linked SNPs rs638944 and rs600491 differed highly 
significantly both in males and females. As we did not find any significant allelic or 
genotypic single SNP association with AD in females, it was generally an interesting 
finding.  
Seladin-1 is a cholesterol synthesizing enzyme (Waterham et al. 2001) that protects cells 
from oxidative stress and A  mediated toxicity (Greeve et al. 2000, Wu et al. 2004) and is 
known to be selectively downregulated in affected brain areas (Greeve et al. 2000). Because 
of the ability of seladin-1 to reduce the activity of caspase 3 enzyme (Greeve et al. 2000) and 
to organize the DRMs and thus influence the APP cleaving process (Ledesma et al. 2003) 
and activity of A 42 degrading enzyme plasmin (Ledesma et al. 2000), it is a plausible 
candidate for AD risk association studies.  
It has been suggested that 17  –estradiol regulates seladin-1 expression levels and that way 
mediates the protective effect of estrogen against A  toxicity (Peri & Serio 2008). Our 
finding that certain DHCR24 polymorphisms have a significant effect on AD risk only in 
males suggests that there might be a gender specific factor involved in the risk 
development and estrogen is in that sense a good candidate.  
We did not find any association between single SNP genotypes or haplotypes and CSF tau 
or ptau levels, but our haplotype finding implies that certain DHCR24 haplotype carriers 
may have an increased risk of AD. The mechanism for the increased risk in certain 
genotype or haplotype carriers may lie in an altered expression of DHCR24 or the stability 
of seladin-1 and thus an altered level of resistance to A toxicity (Wu et al. 2004) or level of 
active plasmin (Ledesma et al. 2003). In our study single marker, haplotype and biomarker 
assessments led to the conclusion that DHCR24 gene may be associated with AD risk. 
Our study assessment with relatively small group of patients and controls and a use of 
stratification may have increased the risk of false positive findings and we tried to diminish 
that risk using the Bonferroni correction. The low number of men in the study group may 
have also diversed the results, especially when the men and women group were compared 
in the subgroup of patients with known CSF biomarker levels. Despite of these limitations 
our findings that DHCR24 gene may be associated with AD risk especially in men would 
make a good candidate for further studies concerning DHCR24 gene genotype carrier status 
and possible differences in the activity and stability of seladin-1 and the level of oxidative 
stress in the brain. Further studies should preferably be assessed with larger study group 
and stratification with gender. 
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7 Conclusions 
 
The aim of this thesis was to genetically characterize Alzheimer’s disease –related risk 
genes in Eastern Finnish population. We focused on genes involved in cholesterol 
metabolism whose gene products effect on A  clearance in the brain. Based on our study 
findings, we can make the following conclusions: 
 
1. The LDLR gene may associate with AD risk and the levels of CSF A tau and ptau in 
females. It also seems that the association of certain LDLR gene polymorphisms and AD 
may be gender specific. 
2. Our findings suggest that SOAT1 gene is only a minor risk factor in AD. 
3. The DHCR24 gene, which encodes seladin-1, may be associated with AD risk and that the 
risk may be gender dependent via some unknown modulator. 
 
In conclusion, the findings reported and discussed in this thesis gave new information on 
the association between cholesterol metabolism genes and AD and on their association with 
CSF AD biomarker levels. These studies further our knowledge and understanding of the 
pathogenesis of AD. 
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Fatty aciD MetaboLisM genes LDLr, soat1 anD DHcr24
anD aLzHeiMer’s Disease risK
Alzheimer’s disease is a complex disorder in 
which both genetic and environmental factors 
affect the risk and the onset age of the disease. 
This thesis investigates the effects of LDLR, 
SOAT1 and DHCR24 genes on the risk and the 
CSF biomarker levels in Alzheimer’s disease. 
The findings provide new information related 
to the possible gender-specific association of 
certain genetic variants with AD, which may 
be applied in the development of novel bio-
markers and treatment strategies for AD.
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